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ABSTRACT 
DNA replication is the cellular process that ensures the loyal and faithful inheritance of the 
genetic instructions contained in the double-strand DNA molecule from one parental cell to 
each daughter cell. It starts from precise genomic loci known as DNA Replication Origins 
(ORIs). Several tens of thousands ORIs are “licenced” during the M/G1 phase of cell cycle 
to become effective sites of replication start, but only a portion of them are really 
“activated” in S phase. Due to the complexity and the crucial importance of the DNA 
replication, these two regulatory processes must be tightly regulated in both space and 
time. 
Different works have recently shed some light onto the positional identification of ORIs 
and their activation, also thanks to the big contribution given recently by the application of 
the Repli-seq technology, a novel method by which it is possible to follow the progression 
of DNA replication both in space and time. 
Up to now, the time-related features of DNA replication, together with the factors that 
might impact the temporal dimension of this system, are yet poorly studied and described. 
To also try to fill the gap for the lack of standard methods able to recognize differences in 
Replication Timing, we developed a bioinformatic method (DART; Differential Analysis 
of Replication Timing) to accomplish this task. 
 Indeed the application of this procedure to our Repli-seq data was instrumental to answer 
our main question:  
Might an oncogene (e.g. the initiating leukemogenic factor PML-RAR) fulfil, at least in 
part,  its tumorigenic potential eliciting an alteration of the normal replication timing pace 
in cells?  
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To identify genomic regions carrying a potential difference in Replication Timing caused 
by the oncogene endeavour and characterize them, we performed Repli-seq, RNA-seq and 
ChIP-seq experiments using an inducible cellular system, the promonocytic U937PR9 cells 
which, if treated with Zinc, ectopically express the PML-RARα fusion protein and, 
consequently, we integrated these data.  
PML-RARα is the initiator oncogene of the Acute Promyelocytic Leukaemia and it works 
as an aberrant transcriptional factor also recruiting chromatin modifier enzymes to 
promoters of its target genes. 
As a result, we found that, after its expression, PML-RARα indeed exerts a deregulative 
effect on Replication Timing, inducing some regions to replicate earlier, and some other 
later, than in control cells. Characterizing them, we observed a close and specific 
association between these differentially replicated regions and both pre-existing, and PML-
RARα-related, transcriptional status and chromatin structure.  
We learnt that regions presenting a EtoL-shifted replication coincide with ‘active’ 
chromatin foci enriched for direct Down-regulated targets of PML-RAR; at the opposite, 
after expression of the oncogene, regions with a LtoE-shifted Replication Timing show 
moderate epigenetic ‘active’ features and are enriched for indirect Up-regulated 
transcriptional targets of PML-RAR 
It is difficult, at this stage, to envisage more clearly the mechanistic route that might 
explain priorities or temporal precedencies of the processes (transcription regulation, 
chromatin status and Replication Timing) that PML-RAR seems to harm.  
Surely it will be interesting and probably easier, now that a new dowel has been added, to 
better understand the entire picture represented by the complex interconnected actions 
implemented by the oncogene over its malicious assault plan and then figure out how to 
combat them. 
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INTRODUCTION 
Background 
 
The DNA Replication process 
DNA replication is a biological process that allows the faithful and exact inheritance of 
the complete genome from a mother cell to two daughter cells. 
The starting point of such process is the opening of the double helix at precise genomic 
regions, called replication origins (ORIs) which, in turn, are subsequently recognized by 
ORC (Origin Recognition Complex), a protein complex composed by six subunits, 
ORC1~ORC6. At the beginning of the G1 phase, ORC recognizes ORIs and bind to DNA 
via its ORC1 subunit.  
In middle G1 phase, another protein complex, the pre-Replication Complex (pre-RC) is 
loaded the selected ORIs, which are therefore “licensed” (that is, are made “eligible” for 
further activation).  In S phase, other factors are bound to the pre-RC, forming the pre-
Initiation Complex (pre-IC).  
Formation of the pre-IC will then lead to the activation (known as “origin firing”) of the 
licensed origins, allowing DNA synthesis machinery to copy each DNA strand, with the 
DNA synthesis progressing from ORIs in a bidirectional manner (Bell and Dutta, 2002; 
Donley and Thayer, 2013) (Figure 1).  
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Figure 1. Main steps of Eukaryotic DNA Replication  - edited from (Méchali, 2010) 
DNA Replication takes place in well-defined genomic regions, called DNA Replication Origins (ORIs).  
As a first step, ORIs are recognized and bound by a protein complex named Origin Recognition Complex 
(ORC). Subsequently, another group of proteins, the pre-Replication Complex (pre-RC) bound to ORC. Only 
when the pre-RC and ORC are released, the DNA replication begins and replication forks initiate to move in 
a bi-directional manner replicating leading and lagging DNA on opposite strands. 
 
Since the process of DNA replication involves the separation and duplication of two DNA 
strands, it constitutionally puts the genomic DNA into a precarious situation. In addition, 
whereas in bacteria it is merely coupled with cell growth and proliferation, in metazoan 
DNA replication is linked also to cell differentiation. Thus, to make things more complex, 
along with an exact copy of the genome, there is also the necessity to faithfully reproduce 
all of the chromatin features that will be the principal determinants of the cell identity 
(Fragkos et al., 2015).   
Indeed, the progression of the replicative machinery might be hindered by both internal 
and external factors (Figure2).  
As an example, the advancing replicative forks might encounter unusual secondary 
structures, such as dinucleotide or trinucleotide repeats, hairpins, quadruplexes or specific 
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G-rich nucleotide repeats or DNA-RNA hybrids (R-loops).   
On its path, toward the replicating DNA strand, the replicative machinery might also clash 
with other DNA-binding proteins or chromatin proteins, or its advance being hampered by 
a reduction of the nucleotide pool or a depletion in other factors needed for the progression 
of the fork (Hyrien, 2000) . 
Among the endogenous factors that can impair DNA replication, a major threat is posed by 
the collision between the replication and transcription machineries.   
 
 
Figure 2. Factors impairing progression of Replication Fork – edited from (Gaillard et al., 
2015b). 
DNA replication can be hampered by several endogenous factors, such as DNA secondary structures like G-
quadruplex and Hairpins, torsional stress induced by nearby transcription or replicative events, or DNA-RNA 
hybrids. Moreover, progression of the replication forks throughout the genome might be slowed or stalled by 
other circumstances, such as DNA-bound proteins, transcriptional events (which may also lead to collision 
between DNA polymerase and RNA polymerase), or heterochromatin.  
 
 
It is known that ORIs are commonly found within genomic territories usually enriched for 
transcriptional activity, such as promoters, DNase-hypersensitivity sites and open 
chromatin regions and that replication timing and transcriptional activity are influenced 
by the same alteration in chromatin status, such as histones acetylation or methylation.  
The event of a collision between DNA polymerase and RNA polymerase might have 
particularly dire consequences on the fate of a cell. Such accidents, indeed, might give 
rise to cell death or, worse, to aberrant chromosomal events (e.g. recombinations), DNA 
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damage, and in general DNA instability, rising the probability of malignancies. (Helmrich 
et al., 2013). 
Taking into consideration the external insults that might interfere with a correct replication 
of DNA, an important contribution is given by oncogenes. As an example, it is known that 
oncogenes might activate a cascade of signals resulting in the deregulation of replication 
origin activation, leading to cellular hyper-proliferation (Hills and Diffley, 2014). 
 A hyper-activation of ORIs might induce a stalling of the replicative fork or to a fork-to-
fork collision leading, in turn, to DNA damage, senescence and cellular death. Such events, 
in general, are however successfully managed by the DNA damage repair system. When 
these systems fail to prevent the damage, though, cells might undergo DNA instability and 
oncogenic transformations (Di Micco et al., 2006; Jones et al., 2013) (Figure 3). 
 
 
Figure 3. From aberrant DNA replication to cancer – edited from (Halazonetis et al., 2008) 
DNA replication is a fine-tuned process, which starts at the beginning of the cell cycle and terminates at the 
beginning of the G2/M phase, when cell is ready to divide into two daughter cells. During this process, DNA 
double helix is open, stretched, twisted and scanned by different protein complexes. In the meanwhile, other 
processes, such as transcription, take place in regions nearby the one being replicated. For this reason, if a 
tight regulation fails to be achieved, a series of events (e.g. DNA damage, nucleotide insertions, duplications) 
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might lead to an aberrant replicative process which, in turn, might lead to genomic instability and, possibly, 
an oncogenic transformation of the cell. 
 
 
Therefore, cells have implemented a series of strategies to regulate the DNA replicative 
process, in order to dramatically reduce the possibility of undesired accidents. 
The main approach adopted by the cells to overcome such events and ensure transmission 
of an exact copy of the genome from one cell to another mainly resides in a tight regulation 
of DNA replication.  
These control mechanisms translate mostly in two different interdependent aspects of the 
DNA replication that are the “space” and the “time”.  
In particular,  
the Spatial regulation refers to the: 
 Recognition of replication origins by the Origin Recognition Complex (ORC) 
during the transition from M to G1 phase. 
 Assembly of a pre-Replication Complex onto the selected origins in mid-G1 phase. 
the Temporal Regulation applies to the: 
 sequential and temporally ordered activation of licensed origins throughout the S-
phase. By this regulative program, every genomic region will be replicated 
according to the temporary pattern attributed to the licensed ORIs contained in it 
and, therefore, by the specific replication timing of the region itself. 
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Control mechanisms of DNA Replication  
 
Spatial Regulation 
 
Recognition of Origins 
 
While in bacteria, the initiation of DNA replication is achieved by the binding of a single 
initiation protein, DnaA, to the oriC, that is the only origin of replication present in these 
organisms, studies in Saccharomyces cerevisiae led to the discovery that the DnaA 
equivalent in eukaryotes is a protein complex: the Origin Recognition Complex (ORC), a 
protein complex consisting of 6 different subunits: ORC1~ORC6.  
Differently from bacteria, where binding of DnaA to oriC is sufficient to start replication, 
the recognition of replication origins in yeast depends by both the binding of ORC to a 11 
bp AT-rich consensus sequence (ACS, ARS consensus sequence), and the presence of a 
precise chromatin context (Bell and Stillman, 1992; Eaton et al., 2010; Leonard and 
Grimwade, 2010).  
On the other hand, in metazoan the number of ORIs is much larger than in lower 
eukaryotes and ORC does not exhibit any sequence specificity (Schaarschmidt et al., 2004; 
Vashee et al., 2003).  
ORC binding to DNA, however, is not random, and studies on elements required for 
ectopic replication from mammalian replicators suggested that recognition of replication 
origins might be strongly context-dependent, relying on regions enriched for dinucleotide 
repeats, matrix attachment regions (MARs), and AT-rich sequences (Altman and Fanning, 
2004; Debatisse et al., 2004; Paixão et al., 2004; Wang et al., 2004).  
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Assembly of the pre-Replication Complex and its regulation 
 
Soon after ORC binding to DNA during the transition from M to G1 phase, other proteins 
are sequentially assembled on the selected ORIs to form a protein complex known as pre-
Replication Complex (pre-RC).  
The completion of the pre-RC on an ORI is known as “origin licensing” and may be 
followed, in S phase, by the “activation” of that origin and its subsequent replication.  
Furthermore, as explained further on, origins can only be licensed and activated once per 
each cell cycle. Licensing is achieved during the middle part of the G1 phase, a period also 
referred as “Origin Decision Point” (ODP) (Wu and Gilbert, 1997). 
 As a first step, Cdc6, complexed with ATP, is bound to ORC. Successively, Cdt1, 
followed by MCM2-7, join the Cdc6-ORC-DNA complex (Figure 4). 
 
Figure 4. Formation of a pre-Replication Complex onto a DNA Replication Origin – 
edited from (Aladjem, 2007) 
After ORI recognition by the ORC, ATP-bound Cdc6 binds to ORC, followed in rapid succession by Cdt1 
and MCM2-7. Binding of MCM2-7 to the DNA-ORC-Cdc6-Cdt1 complex is known as “Origin Licensing” 
and it is a ‘conditio sine qua non’ for a genomic region to serve as a replication origin. 
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The ATP bound to Cdc6 is hydrolysed, and this reaction stimulates the dissociation of 
Cdc6 from the complex. In turn, this catalyses the disengagement of Cdt1, which 
consequently prompt the stable binding of the MCM (Minichromosome Maintenance) 
complex to DNA.  
Successively, the ORC-bound ATP is hydrolysed, allowing the dissociation of ORC and 
the reiterative loading of the MCM complex. Loading of the MCM complex onto the pre-
RC brings to origin licensing, and it is the last step of the pre-RC formation, subsequently 
followed by the activation of the origin of replication (Bowers et al., 2004). 
Upon entering the S-phase, part of Cdt1 is bound by Geminin, preventing the loading of 
the MCM complex on the DNA. The remaining Cdt1 is degraded by either a CDK-
mediated ubiquitin-dependent proteolysis or by interaction with PCNA (Proliferating Cell 
Nuclear Antigen). In this way, Cdt1 will not be present during the S phase, in order not to 
cause re-licensing of replication origins, which will in turn lead to re-replication of the 
same genomic region which would, in turn, result into genomic instability (Lee et al., 
2004; Wohlschlegel et al., 2000).  
Activation of the pre-Replication Complex 
 
Activation of the pre-RC is achieved by the assembly of additional replication factors onto 
the licensed ORIs, forming the pre-Initiation Complex (pre-IC), necessary for the 
activation of the MCM2-7 helicase, unwinding of ORI, formation of the Replisome 
Progression Complexes and the bi-directional progression of the replication fork. 
Such process is under the control of two kinases, CDK (Cyclin Dependend Kinase) and 
DDK (Dpf4-Dependent Kinase) which, in turn, trigger a cascade of signal resulting in the 
recruitment of two additional factors, Cdc45 and GINS (a heterotetrametric complex 
formed by the association of Psf1,2,3 and Sld5) .  
Upon their recruitment, Cdc45 and GINS are tightly bound to MCM2-7, forming the 
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Cdc45-MCM-GINS (CMG) Complex.(Symeonidou et al., 2012; Tanaka and Araki, 2013; 
Walter and Araki, 2006) 
 
The loading of Cdc45 on the pre-IC is critical for at least two reasons: 
 Upon formation of the Cdc45-MCM complex, DNA unwinding is initiated 
 Loading of Cdc45 on pre-IC complex allows the recruitment onto the replisome of 
the three DNA-polymerases: DNA-polδ, DNA-polε, and DNA-polα 
It is plausible that the formation of the pre-IC itself might dictate the replication timing of 
licensed origins. Indeed, whereas all the potential (licensed) ORIs are pre-RC-bound, the 
formation of the pre-IC is limited by the availability of the factors being assembled. Thus, 
ORIs with a higher affinity for those factors might have an earlier Replication Timing than 
the ones with a lower affinity.  (Tanaka and Araki, 2013) 
Activation of the pre-RC is a finely tuned process, with the pre-IC being target of several 
kinases involved in the regulation of the cell-cycle checkpoints, as seen for Rad53 (Lopez-
Mosqueda et al., 2010; Zegerman and Diffley, 2010) and Chk1 (Boos et al., 2011) in 
studies involving buddying yeast. 
Other factors contributing to selection of Replication Initiation Sites 
 
Among the other factors that might strongly contribute to the process of origin selection, 
the most mentionable are distal elements, chromatin structures and transcription. 
  
Distal elements 
Two particular cases exemplify the role that genomic sequences distant from the ORIs play 
for the genomic replication of those loci: Chinese hamster DHFR locus (dihydrofolate 
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reductase)(Kalejta et al., 1998; Mesner and Hamlin, 2005) and the Human β-globin locus 
(Aladjem, 2007; Aladjem et al., 1995; Cimbora et al., 2000) 
 
Human β-globin locus 
 Replication of the β-globin locus depends on an origin replication region placed in the 
intergenic region between the β-like and β-globin genes. 
A natural form of β-thalassemia (known as Hispanic Thalassemia) deletes a region located 
~55kb upstream of the β-globin locus. Deletion of the entire region, or part of it, whereas 
leaving the β-globin locus intact, caused a repression of transcription of β-globin genes in 
erythroid cells (Forrester et al., 1990). For such reason, that genomic region is known as 
Locus Control Region. 
 Further on, it was showed that, in transgenic mice bringing the same LCR deletion caused 
by Hispanic Thalassemia (Aladjem et al., 1995; Cimbora et al., 2000), also Replication 
Timing was altered, with a shift from early to late replication, most probably because 
replication of the β-globin locus was caused by an initiation region located many kilobases 
downstream (Aladjem, 2007).  
 
DHFR in Chinese hamster ovary cells 
In 1998, Kalejta and colleagues (Kalejta et al., 1998), and as successively reported by 
Mesner and Hamlin in 2005 (Mesner and Hamlin, 2005), found a 55kb intergenic region 
enriched with replication origins between DHFR and 2BE2121 genes in Chinese Hamster 
Ovary cells (CHOC).  
 In wild-type CHOCs, DHFR 3’ UTR region successfully stops transcription of the gene at 
the 5’ boundary of the initiation site, and a deletion of 45kb portion of the intergenic region 
(>90%) showed no effects on initiation of replication (Kalejta et al., 1998). 
On the other hand, after the deletion of the 3’ UTR of the DHFR gene, it can be 
appreciated an elongation of transcription of the locus up to 35kb within the intergenic 
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region, with dramatic reduction of the efficiency of the initiation of replication, and a 
replication timing undertaking the whole S-phase in opposition to the original 3-4 hours. 
 By restoring the deleted DHFR gene 3’ UTR segment, the original efficiency of initiation 
of replication is fully restored, thus showing that the wild-type 3’ end of the DHFR gene 
constitute a regulatory element not only for the gene, but also for the local cluster of 
replication origins (Mesner and Hamlin, 2005). 
Chromatin structure 
 
There are evidences showing that modification of chromatin architecture can affect the 
aggregation of the pre-RC which, in turn, might result in an impairment of the replication 
initiation. 
Indeed, recent studies addressed the importance of chromatin structure not only for the 
transcriptional program, but also to regulate the events leading to the selection and 
activation of replication origins. 
As showed in studies on yeast, initiation or replication is facilitated by mutation in histone 
deacetylases (HDACs), as in the case of Sir2 (Pappas et al., 2004).  
In another case, in human cells, mutations on HBO1, an acetyl-transferase, negatively 
regulated the assembly of the pre-RC. Indeed, after the inhibition of HBO1 expression, the 
MCM complex failed to load onto chromatin, thus affecting the correct assembly of the 
pre-RC on replication origin, suggesting an active role of Acetylation and Deacetylation in 
the correct formation of the pre-RC (Burke et al., 2001; Iizuka et al., 2006).  
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Transcription and topology 
 
Transcription can be regarded as both as a positive or negative regulator of initiation of 
replication of certain loci. 
Indeed, actively transcribed gene usually coincide with a negative regulation of replication, 
enacted by either silencing of replication origins inside the gene (not to have RNA and 
DNA polymerases to occupy the same genomic region and thus avoiding collisions) or by 
reducing the size of the initiation of replication region (Mesner and Hamlin, 2005; Sasaki 
et al., 2006).  
Conversely, transcription might be indirectly linked to activation of origins by the 
topological changes induced by the transcriptional machinery. 
As reported in different works (Ghosh et al., 2004; Haase et al., 1994; Kohzaki and 
Murakami, 2005; Nieduszynski et al., 2005), transcription factors might aid selection of 
Initiation Sites by altering local chromatin structure. The chromatin structure generally 
inhibits DNA replication as well as transcription since it reduces accessibility of proteins to 
DNA. In transcription, transcription factors counteract this inhibitory effect of chromatin 
by changing the local chromatin structure surrounding their binding sites. The case of the 
β-globin LCR discussed above can be cited as an example.   In fact, this region contains 
several binding sites for different transcription factors, whose binding might change the 
chromatin status in a way which is also favourable for replication. 
 
As an example negative supercoiling is induced as a consequence of the progresses of the 
transcriptional bubble on the DNA and, on the other hand, negative supercoiling favours 
the unwinding of the DNA double helix.  
In this way, the negative supercoiling caused by two transcriptional machineries 
progressing in diverting ways, might increase accessibility of chromatin and favour the 
binding of the pre-RC. This hypothesis seems to be supported by a recent finding 
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illustrating that divergent transcription takes place in most of transcriptional active genes. 
In such way, then, the genomic regions between the divergently moving RNA polymerases 
might be kept nucleosome free, allowing a more efficient origin activation by assembly of 
pre-RC (Seila et al., 2009).  
 
 
 
 
TEMPORAL REGULATION OF DNA REPLICATION 
 
Two are the main properties, which describe the temporal control of the replication route: 
the plasticity of the replication origins selection and their sequential activation. 
 
Plastic Activation of Selected DNA replication origins  
Involving only a portion of the licenced ORIs, at a first glance activation of replication 
origins might look like a very inefficient process. 
Indeed, in yeast, only 50% of origins seems to be activated and, in metazoan, this 
efficiency sensibly drops to a mere 5-20% (Hamlin et al., 2008; Heichinger et al., 2006).  
Though, what might be regarded as an ineffective process, actually, is one of the most 
powerful mechanisms to regulate the replicative process: the plasticity of the origin 
selection. 
Such level of regulation was revealed in studies by Taylor in 1977 (Taylor, 1977), in which 
Chinese hamster ovary cells were subjected to a treatment by fluorodeoxyuridine, a 
compound that inhibits the conversion from dUMP ( deoxyuracilmonophosphates) to dTMP 
(deoxythyminemonophosphates) thus causing a reduction in the available thymidine pool. 
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After treatment, DNA synthesis was analysed by labelling newly synthesized DNA with 
tritiated thymidine and visualized by DNA fibre autoradiography. 
The results showed that, consequently to starvation for thymidine, distances between the 
labelled segments on DNA fibres were reduced, as were also the rates of fork movements 
(Gilbert, 2007). 
Thus, when fork progression is impaired by external factors (like, in this case, a depletion 
of the nucleotide pool), cells try to compensate by increasing the number of active origins, 
in order to achieve the completion of the S phase within the normal time. 
Conversely, by adding adenine and uridine, replication fork speed was accelerated, with a 
consequent reduction of active origins (Conti et al., 2007).  
Accordingly, DNA replication origins can be divided into three classes: constitutive, 
flexible and dormant (DePamphilis, 1993) (Figure 5).  
‘Constitutive’ are origins that are always used in any cell type and represent the minority of 
all of the DNA origins in a cell. 
‘Flexible’, instead, are origins which are stochastically used in different cells and/or in 
peculiar conditions (as the change of chromatin context during cell development and 
differentiation), and that might account for the low efficiency of origin activation in 
eukaryotes described above in this paragraph. 
‘Dormant’, on the other hand, are inactive origins which are set as a “back-up plan”, in 
case the normal replicative process is hindered by either endogenous or exogenous events. 
What might seem a “surplus” of origins might instead play a role in the maintenance of 
genomic integrity. In fact, given the impossibility of the selection of new DNA replication 
origins in S phase, the activation of such origins might rescue situations in which forks are 
stalled or slowed down (Blow et al., 2011; Woodward et al., 2006).  
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Figure 5. Different types of DNA Replication Origins  –  edited from (Fragkos et al., 2015)  
a) DNA Replication Origins can be divided into three classes: 
    Constitutive ORIs: DNA Replication Origins which are always active without differences between cells in  
     the same pool or even between cell lines 
    Flexible ORIs: These ORIs are activated in a stochastic way, so that some cells will “fire” them, whereas 
in  
    same other cells they will be kept inactive 
    Dormant ORIS: This class of DNA Replication Origins are always keep inactive, and activated only in 
case  
    nearby ORIs are unable to be activated. 
b) Activation of a Dormant ORI: Dormant ORIs are intended as a “back-up plan” for cells in case something  
    interferes with correct DNA replication. As an example, in case of a replication fork being stalled, nearby  
    Dormant ORIs can be activated in order to resume the replication for that particular genomic region. 
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Sequential activation of Replication Origins – Replication 
Timing  
The second layer of temporal regulation of DNA replication is the activation of replication 
origins at different times of the S-phase. Depending on which temporal point of the S 
phase they are activated, origins are classified as early, middle and late replicated ones 
(Figure 6).  
 
 
Figure 6. Spatial and Temporal regulation of DNA replication .  
DNA replication must be tightly regulated in order to allow a faithful inheritance of the genome from a 
mother cell to two daughter cells. Such regulation exerts in two, interconnected, ways. First, a spatial 
regulation is carried out, with the selection of DNA Replication Origins. As a next step, following a 
temporally regulated pattern, selected ORIs will be activated in a sequential way, each with its own timing 
(Replication timing), throughout the S phase.  
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Biological importance of Replication Timing  
 
As reported in a review by Pope, Hiratani and Gilbert (Pope et al., 2010a), the existence of 
a Replication Timing might be explained by the interconnection between replication and 
changes in the chromatin structure of the locus being replicated.  
Indeed, if replication might change the chromatin status of the genomic region interested 
being actively replicated, then different chromatin conformations might be favoured during 
different parts of the S phase. To cite an example already reported, β-globin genes are 
replicated, and transcribed, in early S phase in erythroid cells, whereas in non-erythroid 
cells the same genes are transcribed and replicated in late S phase.  
Experimental evidences seem to support this model. Two studies (Lande-Diner et al., 
2009; Zhang et al., 2002) are reported as an example.  
In one study (Zhang et al., 2002) the investigators injected a reporter plasmid in 
asynchronously rat cells, and consequently measured the expression of the plasmid, 
together with the nucleosome composition, in early and late replicating cells. What they 
found was that efficiency of transcription was much higher in early replicating cells, than 
in those in late replication, and that early S phases correlated with a higher histone 
acetylation. 
In another study, (Lande-Diner et al., 2009), DNA plasmids were microinjected in 
replicating cells and their acetylation levels studied. As a consequence, plasmids injected 
in early replicating cells, that therefore did not undergo any further replication, remained 
acetylated, whereas those microinjected in late S phase were found packed with histones 
and, therefore, presenting a deacetylated state.  
Another study conducted on Drosophila (Bell et al., 2010), showed a positive association 
between active and repressive histone modifications with early and late replication timing.  
Indeed, Bell and colleagues found that, whereas early replicating regions showed an 
enrichment for acetylation (H4K16Ac), a notorious marker for “open chromatin”, histones 
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in late replicating regions were “decorated” by methylated residues (H3K27me3), showing 
reduced accessibility and chromatin compaction. 
 
Replication Timing has also a fundamental role in cell development and differentiation. 
As reported in different studies in literature (Hiratani et al., 2008, 2010; Ryba et al., 2010) 
conducted on both murine and human systems, chromatin reorganization during cellular 
development and differentiation is associated with a change of replication timing of large 
(200kb-400kb) replication domain.  
During differentiation of both mESCs (murine Embryonic Stem Cells) and hESCs (human 
Embryonic Stem Cells), early to late shifts of replication timing can be observed in regions 
associated with down-regulation mESC-specific genes and chromatin inaccessibility, 
whereas late to early shifts were seen in regions associated with up-regulated genes 
associated with a particular cellular “differentiated state”. 
An “extreme” example to an early-to-late shift in replication timing associated with stable 
lineage-dependent repression of chromatin status can be found during the inactivation of 
the X chromosome (Xi, “X inactivation”).  
Interestingly, stable repression of chromatin status occurred during Xi is maintained in 
partially induced Pluripotent Stem Cells (piPSCs) which reprogramming was obtained 
from partially differentiated mESCs which already underwent early-to-late shifts in 
replication timing (which, in females, includes Xi). Conversely, except for those 
replication domains interested in Xi, all the others early-to-late lineage-dependent shifts in 
replication timing could be reverted (Hiratani and Gilbert, 2010). 
 
Moreover, Replication Timing is an evolutionary conserved feature among closely related 
cell lines, as observed in comparative studies in mESC, hESC and differentiated human 
cell lines (Ryba et al., 2010).  
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In their work, the authors underlined how close similarities in Replication Timing, for the 
same replication domains, existed between in different species for similar cell lineages as 
for hESC, mESC and mEpiSCs (mouse Epiblast-derived Stem Cells), and between mouse 
and human lymphoblasts.  
On the other hand, Ryba and colleagues observed significant differences in Replication 
Timing could be observed between cell lines in different developmental stages, such as 
between hESC/mESC and lymphoblastoid cells, with changes involving more than one 
third of the genome.   
 
In addition, Replication Timing correlates with spatial compartmentalization of chromatin 
in nuclear territories, with a radial symmetry between late replicating loci, localized on the 
nucleus periphery, and early replicating domains, placed more toward its centre.  
Coherently, shifts in replication timing during development correlate with chromatin 
spatial reorganization, with late-to-early and early-to-late shifts in Replication Timing 
causing a “swapping” of positions in replication domains for nuclear territories  (Hiratani 
et al., 2008, 2010). 
 
Another plausible option for the existence the replication timing associates the regulation 
of replication timing with preservation of important genomic regions. 
For example, it is known that early replicating regions have a lower mutational rate when 
compared to late-replicating regions (Chen et al., 2010; Lang and Murray, 2011; 
Stamatoyannopoulos et al., 2009).  
Therefore, in a scenario where late replication timing is directly associated with mutation 
rates, the replication of gene-rich genomic regions in the early moments of the S phase 
might reflect an evolutionary pressure to concentrate the nucleotide pools and DNA-repair 
capacity in early S phase, to lessen the probability of mutational events in those regions. 
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As an example, early replicated regions might be the first to have the possibility to undergo 
DNA repair by homologous recombination, being their sister-chromatid template 
immediately available as long as the replication process proceeds. 
Causes and consequences of changes in Replication 
Timing 
 
Given the vast association that Replication Timing has with transcription, and chromatin 
structures, and given the pivotal regulative role Replication Timing has on cellular 
differentiation and development, it comes natural that a deregulation of such process would 
have dramatic consequences on the cell fate is largely expected.  
Therefore, defects in replication timing might be caused, or mirrored by, genetic changes, 
changes in gene expression and epigenetic changes. 
 
Genetic changes 
A first association between genetic changes and deregulation of replication timing can be 
appreciated by exposing cells to different DNA damaging agents. Indeed, cells treated with 
hydrogen peroxide or ionizing radiation, show an aberrant replication timing, up to a 
whole-chromosome delay of replication timing (Brás et al., 2008; Breger et al., 2004; 
Korenstein-Ilan et al., 2008).  
A chromosome-wide delay might, in turn, become a cataclysmic genome-wide event. 
Indeed, a delay in replication timing interesting a whole chromosome might result in 
chromosome structure instability, with a possible higher rate of chromosomal 
rearrangement. 
 Even though such structural rearrangements are usually seen only on the concerned 
chromosome, other chromosomes might engage in inter-chromosomal translocation with 
the delayed chromosome. Such event closely resembles chromothripsis, a phenomenon 
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present in some cancer malignancies, in which one or multiple chromosomes, or 
chromosome arms, are fragmented and then reassembled at random (Breger et al., 2005; 
Stephens et al., 2011).  
Changes in gene expression 
As already extensively addressed before, there is a strong mutual interconnection between 
replication and transcription. In addition, different studies have shown that the deregulation 
of the expression of key-genes involved in replication (such as proteins of the ORC 
complex and CDKs) is followed by abnormalities in replication timing. 
 Indeed, in Drosophila, it was observed that a mutation in ORC2, one of the six subunits of 
the ORC complex, is responsible for an aberrant loading of the pre-RC onto DNA 
replication origins, causing an elongation of the S phase with a consequent early-to-late 
shift of Replication Timing, with some regions of euchromatin replicating later than 
heterochromatin (which usually is replicated in the very last moments of the S phase) 
(Loupart et al., 2000). 
In another study conducted on Xenopus Laevis, it was seen that mutations targeting Cdc7 
and Cdk2, two S phase–promoting kinases (Shechter et al., 2004),resulted in an anomalous 
origin licensing and activation, with consequent deregulation of Replication Timing. 
Moreover, replication timing is impacted by deregulation of expression of genes involved 
in chromatin modification. In fact, the deregulation of expression of chromatin-modifying 
genes can cause long-range repercussions, with a change of replication timing of distant 
regions, even on chromosome different from the one being directly interested. This 
situation has proved to be true by a study conducted on Drosophila, where the deregulation 
of HP1 (Heterochromatin Protein 1) caused the change of replication timing in 5-10% of 
total genomic loci (Schwaiger et al., 2010).   
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Epigenetic changes 
Different studies have proven that chromatin acetylation or methylation profoundly 
impacts on replication timing.  
As a proof of concept, a study can be cited (Goren et al., 2008), where the investigators 
measured acetylation levels in the β-globin domain in erythroid and non-erythroid cells, 
retrieving and hyper- and hypo-acetylated chromatin status in the former and in the latter, 
respectively.  
In addition, to test if acetylation occurring at replication origins could be representing an 
epigenetic mark for early replication, they forcefully acetylated the β-globin domain in 
non-erythroid cells, and caused deacetylation in the domain present in erythroid cells, and 
found that, consequent to acetylation and deacetylation, late-to-early and early-to-late 
shifts could be observed, respectively, in non-erythroid and erythroid cells. (Goren et al., 
2008). 
In the same fashion, other different studies have also proved that changes of the histone 
marks signatures inevitably follow a change in replication timing (Aparicio et al., 2004; 
Vogelauer et al., 2002a; Zappulla et al., 2002).  
 
Aberrations in Replication Timing and cancer  
 
Defects or abnormalities in replication timing seem to be linked with various types of 
cancer, such as breast (Fritz et al., 2013; Grinberg-Rashi et al., 2010; Kazanov et al., 
2015), prostate (Dotan et al., 2004) and lung cancer (Kazanov et al., 2015), and different 
scenarios can be hypothesized to explain this phenomenon. As an example, as previously 
addressed, DNA damage might bring deregulation of replication timing which, in turn, 
might cause genomic instability. Genomic region particularly susceptible to DNA damages 
related to shifts in replication timing are the so-called transition regions, genomic loci 
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placed between early replicating and late replication domains. In particular, whereas in 
replication domains forks move bidirectionally, transition regions are replicated only by 
one replicative fork. Thus, a stall or an aberrant progression of the fork throughout the 
genome might be reflected into an aberrantly replicated transition regions, with either short 
or long-distance repercussions on nearby genomic loci (Watanabe and Maekawa, 2010).  
Or, alternatively, an early-to-late shift in a particular genomic region might result in the 
silencing of a tumour-suppressor gene (De and Michor, 2011). 
Indeed, as briefly described before, early replicating regions tend to have a lesser amount 
of mutations than late-replicating ones, with late replicating regions presenting an higher 
degree of deletions than their early-replicating counterpart. 
 
 
Another way to promote genomic instability and cancer transformation is achieved by 
disrupting the temporal program of replication origins activation, such as increasing the 
number of active origins per genomic region. Such is the case, as an example, of Myc, 
Cyclin-E and H-Ras which, if overexpressed, induce DNA damage by a hyper-activation 
of DNA replication origins (Di Micco et al., 2006; Dominguez-Sola et al., 2007; Jones et 
al., 2013).   
Indeed, an hyperactivation of replication origins might create conflicts between replication 
and transcription machineries, leading to DNA damage and fork stalling. On its turn, fork 
stalling might induce activation of dormant origins, thus increasing the chances of fork-to-
fork collisions and further accumulation of DNA damage.  
Moreover, it has been showed that changes in replication timing play a critical role in 
leukemic cells, with 10-20% of genome being replicated with different replication timing 
when compared with normal controls (Ryba et al., 2012). 
Change of replication timing was not restricted to one particular genomic region, but 
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interested all chromosomes, and was evenly spread throughout the genome. Furthermore, 
even with slight differences depending on the type of leukaemia, changes in replication 
timing were common to all collected samples. 
Many of the shifts in replication timing occurred near regions undertaking genomic 
rearrangements, with one change in replication timing occurring in a common site of 
translocation in leukemic cells.  
Even if all of the samples shared the same change of replication timing associated with 
translocations, not all of them actually showed the translocational event, thus suggesting 
that changes in replication timing might possibly predispose chromosomes to translocation.  
Finally, all of the replication changes were generally late-to-early shifts, with only fewer 
early-to-late shifts in replication timing. 
 
 
Genome-wide studies on DNA Replication – 
Identification of ORIs 
 
Some noteworthy efforts have been made to identify ORIs and characterize their features. 
Unfortunately, as reported in a review by Gilbert (Gilbert, 2010), all of the studies 
conducted so far show a lack of reproducibility. Up to now, the only two methodologies 
use to gain information about ORIs are based on the isolation and successive hybridization 
of short nascent strands (SNS) or onto the isolation of the replication bubble. 
Isolation and hybridization of short nascent strands 
This technique is based on the knowledge that origins move bi-directionally and therefore, 
for each origin, there are two protruding newly-replicating single-stranded DNA strands. In 
theory, if applied on asynchronously growing cells, the abundance of short nascent strands 
(SNSs) should be proportioned to the number of ORIs being activated throughout the 
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whole duration of the S phase. In practice, this technique has different practical drawbacks. 
The major is that, since SNSs just represents origins being fired, it might not be a complete 
map of all (or most of) the licensed origins in the cell population. 
 Two studies using this technique in Hela Cells (Cadoret et al., 2008; Karnani et al., 2010) 
identified nearly one thousand ORIs, covering approximatively 1% of the human genome 
as mapped by the ENCODE (https://www.genome.gov/10005107/) database.  Though, 
even if using the same methodology, they showed an overlap of just 14%, even if the 
identified ORIs were all enriched for TSSs. (Transcription Start Sites). 
More recently, another study used the SNSs technique coupled with next-generation 
sequencing (Martin et al., 2011), similarly describing an enrichment of ORIs near TSSs 
and hypothesizing a possible interconnection between DNA transcription and replication. 
Bubble trap 
This technique relies on the hypothesis that actively replicating ORIs, given the bi-
directional progress of the replication fork, are virtually circular DNA molecules. Such 
molecules could be then “trapped” in an agarose gel, the DNA fragments purified, cloned 
into a vector and successively analysed (Mesner and Hamlin, 2009). Differently from the 
SNSs technique, this method can potentially allow not only the identification of actively 
replicating origins, but of entire clusters (Mesner et al., 2011).  
However, even though also the bubble-trap technique shows an enrichment for ORIs near 
TSSs and genebodies, this methodology displayed little accordance with the studies 
conducted by the SNSs technique, with an overlap of ~10-33% (Gilbert, 2010) (Figure 7). 
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Figure 7 –  Overlap between different studies aimed at the identification of ORIs . 
Mainly, two methodologies have been used attempting to the identification of ORIs: SNS and Bubble-trap. 
Unfortunately, experiments run with both techniques not only have uncovered only ~1% of the genome but 
also showed a poor overlap among them. 
 
Orc1 as a proxy for genome-wide of ORIs 
A novel approach, different by the aforementioned two, is the one performed in HeLa cells 
by Dellino and colleagues (Dellino et al., 2013a).  
By putting together an ultracentrifugation step of cross-linked chromatin, anti-ORC1 ChIP-
sequencing and Repli-seq (a methodology which will be described shortly) into a novel 
approach, it was possible not only to exactly pinpoint the position of ORIs all over the 
genome, but also to know in which fraction of the S phase such origins were activated.  
In this study, the investigators found ~13,000 ORIs, more than ten times the number of 
DNA replication origins found by the two aforementioned techniques. Furthermore, they 
were able to link both the number and the efficiency of ORIs with replication timing, 
showing that as the number of ORIs progressively decreases during the S phase, with 
~4,000 ORIs in S1 and ~700 in S6, so was the height of ORC1 peaks. 
 
In addition, in concordance with literature, they found a strict association with ORIs and 
expressed genes,  with ~17% and ~28% of ORC1 sites co-localizing near highly and 
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moderately expressed genes (high efficiency ORIs) and with the remaining ~55% being 
localized near TSSs of ncRNAs (non-coding RNAs) or within the genebody (low 
efficiency ORIs). 
 
Genome-wide studies on DNA Replication - Repli-seq 
Characterization of Replication Timing as a proxy to study of the DNA replicative process 
and its regulation, and effects on it deregulation, offers several advantages than the 
identification of Replication Origins.  
As an example, characterization of Replication Timing offers a better reproducibility (Yue 
et al., 2014). In addition, contrarily to studies conducted on ORIS, it allows a genome-wide 
characterization of DNA Replication and its different features (Chen et al., 2010; Farkash-
Amar and Simon, 2010; Pope et al., 2011; Gilbert, 2010) 
A huge contribution to methodologies concerning the study of Replication Timing has 
been given by Hansen and colleagues, in 2010 (Hansen et al., 2010a), when they coupled 
part of an already existing methodology used for the study of Replication Timing  (Hansen 
et al., 1993) with next-generation technology.  
By this new technique, named Repli-seq, they were able to study changes in Replication 
Timing across different cell types, for the same genomic region. 
By this technique, as in the STS method from which it derives, asynchronously growing 
cells are subjected to Bromodeoxyuridine (5-bromo-2'-deoxyuridine, BrdU), a synthetic 
analogue of thymidine. Such pulse allows labelling of newly-replicated DNA, which 
incorporates this compound in place of thymidine. Successively, labelled cells are sorted 
into different sub-fractions, spanning all of the S phase (the cell cycle DNA synthesis 
phase). Sorted cells are therefore lysed, and BrdU-hybridized DNA is fragmented and 
immunoprecipitated by the mean of an anti-BrdU antibody. Finally, BrdU-labelled DNA 
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fragments are sequenced.  
Once plotted on Genome Browser, the ordered profiles of BrdU enriched S-phase fractions 
visually shape in space and time the progression of the DNA replication throughout the 
genome. At low magnification (MegaBases scale) the whole Repli-seq profile is 
characterized by a series of early-to-late transitions (also called “Inverted-Vs”, because of 
their shape), being originated from presumably ORIs enriched regions (Figure 8). 
In his work, Hansen and colleagues compared Repli-seq profiles among different cell lines, 
studying how the Replication Timing for the same regions might change depending on the 
cell type or the cell differentiated status (Figure 9).  Moreover, they took advantage of the 
Repli-seq technique to study, among the other things, an association between Replication 
Timing, transcriptional activity and chromatin status. 
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Figure 8. Repli-seq workflow–  edited from  
(https://www.normalesup.org/~vorgogoz/BioInfoCourses/37-recombination-Cheng.pdf; Dellino et al., 
2013) 
In Repli-seq technique, asynchronously growing cells are subjected to a BrdU pulse, then sorted based on 
their DNA content. Subsequently, BrdU-labelled DNA is fragmented and sequenced. By aligning sequenced 
reads to the genome, for each S phase fraction in which cells have been sorted, is possible to appreciate the 
progression of the replication forks throughout the genome in both space and time. 
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Figure 9. Visual comparison of Repli-seq profiles among different cell lines –  edited 
from (Hansen et al., 2010a) 
In their work, Hansen and colleagues showed that Replication Timing is a feature conserved across several 
cell lines (green square). Differences in Replication Timing among cell lines, are usually characteristic of a 
particular cell lines, thus making Replication Timing a pivotal feature for cell development and 
differentiation. 
 
In the same year, Chen and colleagues refined the Repli-seq method, by estimating a 
Replication Timing quantitative measure computed from the signal of the S-phase fractions 
(Chen et al., 2010), which alone was capable to summarize in single value the timing of the 
Replication process of each portion of the genome (Figure 10).  
Such profile derives from a series of values, named “Replication Time estimator S50” 
(from now on referred as “S50” or “S50 Value”), ranging from 0 to 1. An S50 value is 
defined as “the fraction of the S phase (0 < S50 < 1) at which 50% of DNA is replicated 
(50% of the cumulative enrichment) in a defined genome region “.  
S50 values were computed by linearly interpolating the signals coming from all of the S 
phase fractions, as described in a previous work by Jeon et colleagues, in 2006 (Jeon et al., 
2005). 
Thus, early replication corresponds to low S50 values, whereas high values correspond to a 
later Replication Timing. 
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Figure 10. Replication Timing profile – edited from 
https://www.normalesup.org/~vorgogoz/BioInfoCourses/37-recombination-Cheng.pdf 
From different S phase fraction signals, it is possible to calculate a unique Replication Timing Profile. Such 
profile derives from consecutive values (S50 Values). Each value, consisting in the 50% of the amount of the 
DNA replicated in a genomic interval, is an indirect measurement of the Replication Timing for each 
interval. Furthermore, being S50 values associating amount of DNA being replicated with Replication 
Timing, small S50 values will be addressing early replicating regions, whereas to high S50 values will be 
corresponding late replicating regions. 
 
 
 
 
Up to now, Repli-seq has been used in different studies (Barlow et al., 2013; Debatisse et 
al., 2012; Liu et al., 2015; Polak et al., 2015). In particular, one study (Pope et al., 2014) 
implied massively use of the Repli-seq technique, taking advantage of fifteen different 
Repli-seq experiments performed on just as many different cell lines. 
Unfortunately, though, up to now Repli-seq technique has not been used as a main tool of 
analysis, but only as a way to characterize and compare results with other techniques (see 
below). 
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Leading Hypothesis 
The hypothesis underlying this study has been driven by different evidences linking both 
deregulation of transcription and disruption of the normal chromatin status with 
deregulation of DNA replication.  
Indeed, earlier in this chapter, it has been shown that deregulation of genes involved in the 
first steps of the replicative process is usually followed by deregulation of the replication 
timing (Loupart et al., 2000; Shechter et al., 2004). 
Replication Timing might also be altered by a deregulation of normal chromatin status, 
with hyperacetylation bringing a late-to-early shift and deacetylation causing instead a late 
replication in regions normally being replicated earlier in the S phase (Göndör and 
Ohlsson, 2009; Goren et al., 2008) 
Furthermore, it has been shown that 10-20% of the genome in leukemic cells is replicated 
with a Replication Timing different from control cells. Importantly, deregulation of 
Replication Timing appears to be diffused along the genome, and not restricted to 
particular genomic areas (Ryba et al., 2012). 
Given this, we hypothesized an active role for PML-RARα, the initiator oncogene in APL 
(Acute Promyelocytic Leukaemia), in the deregulation of normal Replication Timing.  
Indeed, given the close relationships among DNA Replication, Chromatin status and 
transcription, we hypothesize that PML-RARα might exert part of its oncogenic activity by 
deregulating the normal Replication Timing of a cell, as a consequence of the deregulation 
of transcription and change of normal chromatin status. 
To test this hypothesis, we took advantage of U937PR9 cells (Casini and Pelicci, 1999) as 
our model system. U937PR9 cell line is a stable clone obtained from monoblastic U937 by 
transfection of PML-RARα cDNA under the control of a Zinc-inducible metallothionein 
promoter. In normal conditions,U937PR9 cells do not express PML-RARα, whereas the 
oncogene is expressed after induction by Zinc, in concentrations comparable to the ones 
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found in APL patients. 
To study changes in Replication Timing after expression of PML-RARα, we will take full 
advantage of the Repli-seq technique, measuring replication timing before and after 
induction by Zinc in cells asynchronously replicating for 24 hours. 
Moreover, to study whether the deregulation of the normal transcriptional programme or 
the normal chromatin status by PML-RARα is able to modify Replication Timing, we will 
take advantage of RNA-sequencing (from now on referred as RNA-seq) and anti-
H3K4me3, anti-H3K4me1 and H3K27Ac ChIP-sequencing (from now on referred as 
ChIP-seq) performed on both normal samples and cells retrieved after 8 hours of induction 
by Zinc. 
 
 
Acute Promyelocytic Leukaemia  
 
Acute promyelocytic leukemia (APL), a sub-type of Acute Myeloid Leukemia, is one of 
the most studied and understood at molecular level blood malignancies. It is characterized 
by a block of differentiation of myeloid precursors, which show a promyelocytic 
cytomorphology, and by a reciprocal translocation between chromosome 15q24.1 and 
chromosome 17q21.2 (Figure11).  
The reciprocal t(15;17) (q24.1;q21.2) translocation found in APL gives rise to the 
expression of a fusion protein, resulting from the fusion of the PML (ProMyelocitic 
Leukemia) locus with the RARα (Retinoic Acid Receptor alpha) one.   
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Figure 11. Reciprocal translocation between chromosome 15 and chromosome 17 results 
in PML-RARα fusion protein –  edited from (Wang and Chen, 2008)  
Reciprocal translocation between chr15q24.1 and chr17q21.2. The main result of such translocation is a 
functioning fusion protein, PML-RARα, together with RARα-PML and an aberrant PML isoform. 
 
 
 
The deriving fusion protein, PML-RARα, is believed to suppress PML activity (which 
normally has a pro-apoptotic and growth suppressor activity) and is known to block 
differentiation of myeloid progenitors by repressing genes normally targeted by retinoic 
acid (Kakizuka et al., 1991; de Thé et al., 1991).  
APL is morphologically categorized by the French-American-British (FAB) classification 
as AML-M3. Up to now, two morphologic variants of APL are known: a “typical” 
(hypergranular) and a “microgranular” (hypogranular) APL. 
Hypergranular APL is the most common form, with ~70% of cases of APL showing its 
morphological features, such as cells presenting bilobed nuclei, and numerous large, red to 
purple cytoplasmic granules  (Sainty et al., 2000).  
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Typical APL is traditionally treated with ATRA (all-trans retinoic acid) (Grimwade et al., 
2000), which is capable to revert of the block of differentiation induced by PML- RARα 
fusion protein (Figure 12). 
Untreated APL has a median survival of less than one month. On the other hand, prognosis 
for APL patients is the better among all the other AML subtypes, with higher chances to 
achieve complete remission after treatment.  
Moreover, clinical trials have proved that 90% of patients affected by APL with classic 
t(15;17) achieve full remission, with low risks of relapse , after treatment consisting of 
ATRA, ATO (arsenic trioxide) and chemotherapy (Wang and Chen, 2008) 
 
Figure 12 –  Block of differentiation in APL and reinstate of myeloid differentiation 
after treatment by Retinoic acid –  edited from (He et al., 1999) 
Expression of  PML- RARα causes block of differentiation and abnormal proliferation in Myeloid 
Progenitors (left). After treating leukemic cells with Retinoic Acid (RA), cells revert block of differentiation 
and resume cellular differentiation (right). 
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PML-RARα 
 
In 1993, Grignani and colleagues (Grignani et al., 1993a) identified PML- RARα as the 
initiator oncogene in APL. The identification was brought by several findings. As an 
example, the (15q24.1;17q21.2.) translocation is found in all of the APL cases, and in 90% 
of times it is the only anomaly discernible in APL patients (Biondi et al., 1991; Pandolfi et 
al., 1992; Tallman and Kwaan, 1992) and that, despite the fact that the translocation might 
imply longer or shorter chromosomal fragments, there will be always formed a functional  
PML- RARα fusion, with a PML and a RARα domains retaining their wild-type functions 
(i.e. DNA-binding domain for PML retinol and DNA-binding domain for RARα ) gene 
(Pandolfi et al., 1992). In addition to PML- RARα, other two proteins, aberrant PML and 
RARα-PML, are generated by the translocation, but won’t be discussed here. 
Usually, oncogenic transformation is acquired after a series of consecutive events.  
In APL, instead, it looks like a single translocation is able to drive an oncogenic 
transformation, alone. This property might be given by the arising, from this translocation, 
of three functioning aberrant proteins (Grignani et al., 1993a), which might greatly reduce 
the number of additional events in order to bring oncogenic transformation.  
In addition, since to PML- RARα retains both PML and RARα functional domains, the 
fusion protein alone is able to tamper with the endogenous PML and RARα pathways.  
Indeed, evidences show that PML- RARα, in vitro, has an affinity and binding specificity 
to retinoids equal to the wild-type RARα (Nervi et al., 1992) and that it is able to regulate 
RARα target genes (Nervi et al., 1992; de Thé et al., 1991, Casini and Pelicci, 1999).  
As been showed by Grignani et al, treating APL patients with Retinoic Acid induces 
differentiation of RA PML/RAR -expressing cell, with a depletion of PML/RAR  
expression. Such phenomenon, might be indeed due to the retain of the wild-type RAR  
properties by PML/RAR  induces differentiation of PML/RAR -expressing cells, both in 
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the patients (Casini and Pelicci, 1999; Grignani et al., 1994) 
Furthermore, PML- RARα is able to dimerize with wild-type PML (Kastner et al., 1992). 
PML is the main component of the so-called “PML Nuclear Bodies”, nuclear structures 
which are supposed to have a role into transcription, DNA replication or post-translational 
modifications (Lallemand-Breitenbach and de Thé, 2010). Therefore, dimerization of 
PML- RARα with endogenous PML might contribute to the deregulation of the cellular 
processes regulated by the PML Nuclear Bodies. 
Mechanistically, PML- RARα exerts its block of differentiation and suppression of 
transcription of retinoic acid target genes by recruiting the histone deacetylase (HDAC) 
complex  (Grignani et al., 1998) and, furthermore, is has been shown that PML- RARα is 
also able to cause hypermethylation of target promoters by actively recruiting 
methyltransferases (Croce et al., 2002), such as Dnmt1 or Dnmt3a.  
In addition to its role as a repressor, Alcalay and colleagues (Alcalay et al., 2003) found 
that PML- RARα might also play as a positive regulator of transcription. Indeed, PML- 
RARα seems to induce transcription in genes already targeted by other fusion proteins 
commonly expressed in Acute Myeloid Leukaemia, such as AML1-ETO and PLZF- 
RARα. 
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MATERIALS AND METHODS 
 
MODEL SYSTEM – U937PR9 CELLS 
U937 is a hematopoietic cell line derived from a lymphoid malignancy of a 37-years old 
patient suffering from histiocytic lymphoma. However, these cells retain myeloid features, 
rather than lymphoid. 
As an example, these cells have the ability to secrete lysozymes, usually produced by 
monocytes and macrophages. Indeed, high levels of lysozyme are usually found in 
monocytic and myeloid malignancies and not in lymphoid leukaemias (Sundström and 
Nilsson, 1976). 
In addition, further phenotypical, cytochemical, and functional analyses have proved that 
U937 cells closely resemble myeloid precursor with a blocked differentiation at the 
promonocytic stage. (Nilsson et al., 1981). 
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Figure13. A U937 cell (Sundström and Nilsson, 1976)   
In this picture, taken by transmission electron microscope (x12,000 enhancement), it is possible to appreciate 
a lobated nucleus, together with numerous cytoplasmatic vesicles. 
 
Furthermore, when stimulated by dihydroxyvitamin D3 and transforming growth factor β1, 
U937 cells are able to revert the differentiation block in myeloblastic stage and proceed 
toward monocytic terminal differentiation (Testa et al., 1993). 
Thus, U937 are per se a good model to test the effects of expression of PML-RARα on 
cellular differentiation. 
In 1993, Grignani and colleagues (Grignani et al., 1993) successfully engineered U937 
cells by transducing them with a vector carrying PML-RARα cDNA under control of the 
inducible mouse metallothionein 1 (MT-1) promoter (Figure 14).  
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Figure 14 –  Original Schema of pMTPR plasmid used to transduce U937 cells  - from 
(Grignani et al., 1993b). 
Mo-MT-1: mouse MT-1 promoter; PML-RARα: cDNA of fusion protein PML-RARα; SVpA: SV40 (Simian 
Virus 40) polyadenylation (termination) region; SV40neo: Neomycin (Neo) gene under control of SV40 
promoter-enhancer. 
 
 
 
Upon infection and selection, the PR9 clone was chosen, based on the high levels of PML-
RARα expressed upon induction by ZnSO4 (Zinc) already after 24 hours.  
More importantly, PML-RARα levels were comparable with the ones expressed in fresh 
APL blasts collected from patients. 
Therefore, for the aim of this project, in order to study possible changes in Replication 
Timing after expression of PML-RARα, we took advantage of a pool of exponentially 
growing U937PR9 cells inducted by Zinc for 24 hours, and a control pool of U937PR9 
cells without any induction.  
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Figure 15. Expression of differentiation antigen before (left) and after expression of 
PML-RARα induced by Zinc (right) –  edited from (Grignani et al., 1993b). 
The expression of several differentiation factors (CD11a, CD11b, CD11c, CDC14 and FcRI) was analysed in 
U937PR9 cells with and without induction of PML-RARα expression by 100 µM ZnSO4, in control cells 
(C), cells treated with  dihydroxy vitamin D3 (D3) and cells treated with both dihydroxy vitamin D3 and 
Transforming Growth Factor β1 (D3+TGF).  
Results are expressed as the percentage of cells positive for the antigens for CD11a, CD11b, CD11c, CDC14 
and FcRI (left) or the mean fluorescence for the CD14 marker (CD14 Mean Fluorescence, CD14MF, right). 
In the left panel, U937PR9 resume differentiation after treatment with both D3 or D3+TGF, whereas in 
U937PR9 expressing PML-RARα after induction by Zinc differentiation is blocked even after treatment with 
either D3 or D3+TGF. 
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Figure 16 –  Expression of PML-RARα in U937PR9 after induction by Zinc.  
Expression of PML-RARα is promoted already after 24 hours of induction by Zinc. Expression of PML-RARα 
remains constant for almost 3 days, and begins degrading after 120 hours since adding Zinc to the cell colture.  
 
 
Repli-seq 
 
Asynchronously exponentially growing U937PR9 cells were collected and incubated for 
45 minutes with 50 µM 5-bromo-2-deoxyuridine (BrdU) (i.e. BrdU pulse).  
For the “Zinc-treated” condition, expression of PML-RARα was induced upon addition of 
100 µM ZnSO4 to cell culture and cells were left growing for 24 hours, prior to the BrdU 
pulse. 
Subsequently, and for each condition separately, cells were DAPI-labelled and sorted by 
FACS into six fractions spanning throughout the S phase (S1, S2, S3, S4, S5, S6.  (Table 
1) 
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FACS  
Sorting Gates Manually reassigned* 
S phase 
fractions Start End Start End 
S1 2.09 2.29     
S2 2.3 2.6   2.61 
S3 2.62 2.94     
S4 2.95 3.26   3.275 
S5 3.29 3.59   3.68 
S6 3.77 4.08 3.68 4 
     Table 1. FACS Sorting Gates according to cell DNA content quantified by DAPI  
* gaps among gates were manually reassigned by equally splitting gap distance among 
adjacent gates  
 
Following sorting, cells were lysed, and DNA extracted and fragmented. BrdU-labelled 
DNA fragments were immunoprecipitated using an anti-BrdU monoclonal antibody 
(Becton Dickinson Cat.no. 347580), assembled into separate Illumina libraries and 
sequenced.  
BrdU-labelled DNA fragments were sequenced by Illumina Hiseq 2000 with 36bp single-
end short reads. Successively, reads were aligned to the reference genome (Hg18) using 
the Barrows-Wheeler Aligner (BWA)  (Li and Durbin, 2009), obtaining an average of  ~20 
million and ~14 million uniquely mapped reads in Replicate1 for the Zinc-treated and 
Untreated conditions, and  ~16 million for both Zinc-treated and Untreated conditions in 
Replicate 2 (Table 2). 
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Unique reads mapped to genome (Hg18) 
  Replicate1 Validation Replicate 
S phase 
fractions 
Zinc-treated Untreated 
Zinc-
treated 
Untreated 
S1 16,452,864 8,684,378 18,026,962 9,447,101 
S2 24,519,006 18,116,761 13,227,563 15,895,253 
S3 18,525,159 12,779,129 28,767,155 19,594,275 
S4 19,603,429 19,607,396 12,081,052 17,884,233 
S5 24,215,342 13,751,038 11,517,206 15,776,376 
S6 18,666,357 12,034,952 13,284,630 19,060,496 
Table 2. Uniquely mapped reads for Zinc-treated and Untreated conditions in 
Replicate1 and Validation Replicate.  
 
   
 
RNA-sequencing and Differential Expression Analysis 
 
RNA-sequencing 
RNA-sequencing libraries were prepared by collecting U937PR9 cells (Untreated and 
Zinc-treated, separately). For Zinc-treated condition, cells were incubated with 100 µM 
ZnSO4 for 8 hours. 
RNA was extracted using Qiagen RNeasy Mini Kit according to manufacturer’s practice 
and libraries were prepared following protocols described in Illumina TruSeq® RNA 
Version 2 and RNA fragments were sequenced with Illumina Hiseq 2000 by 50bp paired-
end short reads. 
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RNA-Seq data analysis 
The sequenced samples were aligned on the reference genome Hg18 (Homo sapiens NCBI 
Assembly 36.1 (GCF_000001405.12))  using TopHat software (Trapnell et al., 2009).  
Mapped sequences were processed with HTSeq software(Anders et al., 2015) with 
parameters: (-m) intersection strict, (-a) skip quality reads less than 1. 
 Differential gene expression analyses including size-factor normalization, shrinkage 
estimation for the distribution's variance and negative binomial distribution were 
performed using the R package edgeR (Robinson et al., 2010). 
 
ChIP-sequencing  
ChIP-sequencing libraries were prepared by collecting 1-5 ng of ChIP DNA from 
U937PR9 cells (Untreated and Zinc-treated, separately) and following instructions as per 
an in-house protocol. For Zinc-treated condition, cells were incubated with 100 µM ZnSO4 
for 8 hours. 
ChIP was performed for H3K4me3, H3K4me1 and H3K27Ac taking advantage of the 
following antibodies: 
H3K4me3: anti-H3K4me3 Active Motif 39159 (Rabbit, polyclonal) 
 H3K4me1: anti-H3K4me1 Abcam    ab8895 (Rabbit, polyclonal) 
 H3K27Ac: anti-H4K27Ac Abcam    ab4729 (Rabbit, polyclonal) 
Immunoprecipitated DNA fragments were sequenced with Illumina Hiseq 2000 by 51bp 
single-end short reads. 
Sequenced reads were aligned on the reference genome hg18 with BWA software (version 
0.6.2-r126) (Li and Durbin, 2009) using presets end-to-end parameters, and discarding 
reads with more than one mapping.  
Duplicate reads were removed with Samtool rmdup version 0.1.19 (Li et al., 2009). 
ChIP-Seq signals were identified using MACS v.1.4.10 (Zhang et al., 2008) with shifting 
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model and dynamic lambda disabled, using a tag size of 51 and the to-large option to scale 
the IP samples to the input sample. 
Uniquely mapped reads for H3K4me3, H3K4me1 and H3K27Ac samples for both Zinc-
treated and Untreated conditions and for input are reported in Table 3. 
 
 
   
 
Zinc-treated Untreated 
H3K4me3 14,410,659 16,615,404 
H3K4me1 22,195,611 26,620,576 
H3K27Ac 42,066,749 25,671,866 
Input 22,168,088 
Table 3 –  Uniquely mapped reads in ChIP-seq Histone marks data  
 
Alignment of Repli-seq and ChIP-seq data, and alignment of RNA-seq data and DE 
analyses were performed by taking advantage of an in-house pipeline developed by 
Luciano Giacò. 
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DART Pipeline 
DART was computed by taking advantage of three different programming languages: shell 
scripting, R (version 3.2.2) and Python (version 2.7.3).  
 
Binning of reference genome 
Hg18 was binned in 100bp intervals by command “makewindows” from the BEDTools 
suite (Quinlan and Hall, 2010), with parameters -g <reference genome> -w 100  
 
Calculation of coverage 
This multi-step process was performed by taking advantage of different tools. 
At first, each S phase fraction signal was converted from bigwig to wig format by 
bigWigToWig (Kent et al., 2010) and, successively, signal underlying each 100bp genomic 
interval was retrieved by “intersectBed” and “groupby”, other two tools of the BEDTools 
suite. 
 
Internal normalization 
TMM normalization was performed by command “calcNormFactors” from edgeR and 
normalizing factors were applied to each S phase fraction, for each condition separately. 
 
Inter-condition normalization 
Quantile normalization was performed by “normalizeQuantiles” in Limma (Ritchie et al., 
2015) R library. 
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Calculation of S50 values 
Computation of S50 values was performed by a custom script kindly provided by Davide 
Cittaro, and described in (Dellino et al., 2013a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 60 
 
RESULTS 
 
Different studies have showed a strict association of Replication Timing with transcription 
(Huvet et al., 2007; Rivera-Mulia et al., 2015), chromatin structure (Donaldson, 2005; 
Lubelsky et al., 2014; Vogelauer et al., 2002), cell development and differentiation (Pope 
et al., 2010). 
In 2010, Hansen and colleagues coupled pre-existing Replication Timing approaches with 
next-generation sequencing technology, devising a novel method known as Repli-seq 
(Hansen et al., 2010). Thanks to Repli-seq, it is possible to study the progression of the 
replication forks throughout the genome and to identify regions containing, or enriched for, 
ORIs.  
In addition, Hansen and colleagues made a first attempt to compare DNA replication 
timing in different cell lines.  
However, in the past years Repli-seq technology has been mainly used to characterize the 
Replication Timing per se, with no studies taking advantage of such method to measure 
and to assign statistically significant differences, at genome scale, in Replication Timing 
between different cell lines or experimental conditions. 
Thus, this work aimed to: i) generate a bioinformatic and statistical procedure to identify 
regions showing differential replication timing between two conditions, and ii) apply this 
method to study possible changes in Replication Timing of promonocytic U937-PR9 cells 
before and after the expression of the PML-RARα oncogene.  
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DART (Differential Analysis of Replication Timing) 
pipeline 
 
In order to evaluate the presence of differences in Replication Timing before and after 
PML-RARα expression, we developed a bioinformatic method to compare, pairwise, 
Repli-seq experiments. 
Such approach, after normalization between BrdU signals of each S sub-phases, to account 
for technical and biological intra- and inter-condition variability, allows genome-wide 
calculation of Replication Timing for each condition and the identification of genomic 
regions showing a statistically significant differences in Replication Timing. The workflow 
of the pipeline is schematized in Figure 17 and will be briefly discussed below. It consists 
of the following main steps: 
 Alignment and coverage calculation 
 Internal Normalization: TMM 
 Signal Transformation 
 Removal of nonspecific signal  
 Normalization between conditions: Quantile Normalization 
 Calculation of Replication Timing 
 Identification of Regions enriched for ORIs (Valleys) 
 Identification of Valleys showing Different Replication Timing   
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Figure 17.  DART pipeline workflow  
The diagram shows, step-wise, the operations’ flow that lead to the identification of regions enriched for 
ORIs with a different Replication Timing between two experimental conditions. 
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The Repli-seq at glance 
During Repli-seq procedure, asynchronously growing cells are pulse-labelled by 
Bromodeoxyuridine (BrdU), a thymidine analogue that is actively incorporated in nascent 
DNA strands, thus labelling the newly-replicated DNA. 
Cells are then stained with Propidium Iodide (PI), a fluorescent molecule that binds to 
DNA by intercalating among the bases, and analysed by Fluorescence-activated cell 
sorting (FACS). 
 FACS measures the DNA content of each cell by means of their PI fluorescence signal 
and fractionates the analysed cells in “n” subpopulations with different DNA content 
(where “n” is the number of the sorting gates which have been chosen). Since total DNA 
content of each cell increases during the progression of the S-phase, each sorted 
subpopulation of cells corresponds to a defined time interval of the S-phase; in our 
experiments n=6 (S1 to S6). 
Sorted cells are then lysed, the DNA is fragmented and immunoprecipitated with an anti-
BrdU antibody and, finally, the immunoprecipitated DNA fragments undergo high-
throughput sequencing. 
In our cell model, a normal cell cycle lasts ~24 hours and one third of them (~8 hours) are 
used for DNA synthesis (S-phase). Since the S-phase was divided into six fractions of 
equal length, each S-phase fraction corresponds to slightly less than 1.5 hours. 
 
 
Alignment:   
For each experimental condition and for each S-phase fraction, the first step of the 
bioinformatic approach is the alignment, on the reference human genome (in this study we 
used the human Hg18 release), of BrdU-positive DNA sequences.  
Visualization of the S1-to-S6 ordered raw alignment on the Genome Browser immediately 
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allows the identification of the expected progression of DNA replication, in space and 
time, as revealed by the Repli-seq assay (Figure 18a). 
Progression of the replication forks is represented by a series of early-to-late transitions, 
called “Inverted-Vs”, which originate from the summit of each “Inverted-V”, known as 
“Inverted-V apex”, regions which are, probably, enriched ORIs. 
 
 
Figure 18 –  From alignment of Repli-seq to Replication Valleys  
a) Aligned Repli-seq S-phase fractions (S1-S6) (raw data), with the characteristic Inverted-Vs (red dotted 
line) and Inverted-V apexes (red dotted circles) 
b) S50 profile of the region, with values ranging from 0 to 1 
c) Replication Valleys.  
 
Calculation of Coverage: 
After sequencing and alignment, the reference genome was divided in 100 bp-long 
consecutive and non-overlapping bins; the underlying BrdU signal of each S-phase fraction 
was calculated for each bin and for each experimental condition. 
 
Internal Normalization: 
Given the nature of the Repli-seq assay, each S-phase fraction (S1-S6) derives from an 
independent sequencing run, but is strictly dependent upon the others since was obtained 
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from the whole S-phase of the same cell population.  
Therefore, an intra-condition normalization step among the S-phase fractions allowed the 
elimination of possible biases introduced by different sequencing depth across samples. 
For this purpose, we decided to apply a TMM (Trimmed Mean of M-values) normalization 
to each experimental condition, separately. 
The TMM is a normalization method firstly described by Robinson and colleagues 
(Robinson and Oshlack, 2010) and largely used for the normalization of RNA-seq libraries 
(Li et al., 2015). By this normalization, it is possible to apply a scaling factor to the library 
size of the samples being studied, thus allowing their direct comparison. 
 
 
Signal transformation:  
Since each region of the genome is replicated only once and only in a specific moment of 
the S-phase, the total signal of the six fractions, in principle, should be the same for each 
bin. As a further normalization step, we therefore transformed the normalized counts of 
each genomic bin in a value expressing the relative quantity of signal found in each 
specific S fraction, with respect to the total signal.  
To this end, for each 100 bp interval, we divided the normalized counts of each Sphase 
fraction by the total Sphase signal (S1 to S6), thus converting the signal from each 100 bp 
interval in six values ranging from 0 to 1. 
This allowed a precise measure of the contribution of each Sphase fraction to the 
completion of the DNA replication for each genomic interval of 100 bp. 
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Subtraction of Total BrdU signal: 
To reduce the background signal in each fraction of the S-phase, we first created an in-
silico pseudo-Total BrdU signal: for each 100 bp interval, we summed up the values from 
each S-phase fraction, and then calculated the mean value. This pseudo-Total BrdU signal 
was then subtracted from each S-phase fraction.  
 
Normalization between conditions by Quantile Normalization:  
TMM normalization might be sufficient to study the Replication Timing of a single 
experiment per se. However, in order to compare two Repli-seq experiments performed in 
control and perturbed experimental conditions, another run of normalization was 
performed, aimed to remove variability between the two conditions due to technicalities 
and not deriving from true biological differences.  
A Quantile Normalization was applied in pairwise combinations between the same S-phase 
fraction deriving from the two experimental conditions (e.g., S1Exp vs S1Ctrl, S2Exp vs S2Ctrl, 
etc.), before the identification of true biological variations between control cells (Control) 
and cells expressing the oncogene (Exp). 
 
Calculation of Replication Timing (S50 values): 
In order to transform the complex replication pattern deriving from BrdU signals from six 
independent S-phase fractions, in a single quantitative value which measures the 
Replication Timing, we used the S50 value, defined as the fraction of S-phase at which 
half of the total DNA from a genomic region is replicated. 
As previously reported (Dellino et al., 2013), the reference genome was divided in 50 kb 
consecutive and non-overlapping intervals, obtaining ~65,000 genomic windows.  
For each condition, and for each 50 kb window, an intermediate cumulative sum (S1, 
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S1+S2, S1+S2+S3, etc.) and a final sum M (M: S1+S2+S3+S4+S5+S6) were computed 
and a S50 value was calculated by a linear interpolation of the two cumulative sums closest 
to M/2. 
Consequently, S50 values close to zero correspond to early-replicating regions, while S50 
values close to “1” correspond to late-replicating regions (Figure 18b).  
 
Identification of Regions enriched for ORIs: 
We primarily focused on Differential Replication Timing at Inverted-V apexes, that show 
smaller S50 values than their flanking regions. 
For Exp and Control cells separately, at each Inverted-V apex we methodologically 
defined an origin-containing region (OCR) as the local minimum value in the S50 profile 
(corresponding to a 50 kb region) extended by two windows (50 kb each) both upstream 
and downstream, for a total 250 kb-long genomic region (Figure 18c).  
Since OCRs appear as depressions in the S50 Profile, as shown in Figure 19, where the 
S50 profile of the entire chromosome 10 is reported, they are also called “Replication 
Valleys” or, simply, “Valleys”. 
 
 
Figure 19 -  Examples of S50 Profile and Valleys.  
S50 profile (solid line) calculated for the whole chromosome 10 and Valleys (circles) 
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Identification of Valleys sharing the same genomic location in the 
two Samples:  
In order to measure differences in replication timing between Exp and Control samples, we 
first focused on Valleys common to the two experimental conditions. At this purpose, we 
calculated the Jaccard index, according to the following formula: 
JI = (A  B / A  B) 
thus corresponding to the intersection between A and B, divided by the union of A and B, 
and selected Valleys showing Jaccard Index equal to or higher than 0.6 in a range from 0 to 
1 (i.e., overlapping for 4, out of 5, 50 kb-long intervals). 
Calculation of difference in Replication Timing - the Diff_S50 
values:  
We then calculated, for each Valley, the difference between the S50 values of Exp and 
Control. 
Such values, termed Diff_S50, were obtained by the formula: 
Diff_S50=min(S50Exp) – min(S50Ctrl)  
A negative Diff_S50 value indicates a late-to-early shift (LtoE) of Replication Timing 
(S50Exp values smaller than S50Ctrl), whereas a positive Diff_S50 value reveals an early-to-
late shift (EtoL) of the Replication Timing (S50Exp values bigger than S50Ctrl). 
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Identification of Valleys with a significant different Replication 
Timing:  
EtoL- and LtoE-shifted Valleys were tested for the statistical significance of the observed 
change of Replication Timing (|Diff_S50 | > 0). At this purpose, we took advantage a 
paired t-test and, based on the results, Valleys were subsequently divided in three classes: 
LtoE-shifted Valleys, showing in the Exp sample S50 values significantly smaller than in 
the Control sample (adjusted p-value ≤0.05); these Valleys showed a late-to-early shift in 
Replication Timing following PML-RAR expression; 
EtoL-shifted Valleys, showing in the Exp sample S50 values significantly higher than the 
Control sample (adjusted p-value <=0.05); these Valleys showed an early-to-late shift in 
Replication Timing following PML-RAR expression. 
 Stable Valleys – Valleys without any significant difference in Replication Timing 
following PML-RAR expression. 
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DART Pipeline applied to Repli-seq experiments in 
U937-PR9 cells upon PML-RARα expression 
 
We run the DART pipeline on our PML-RARα-expressing (Zinc-treated) and Control 
(Untreated) samples and found 1,717 and 1,707 Valleys for the Zinc-treated and Untreated 
conditions, respectively, with ~91% (n=1,560) overlapping Valleys (Figure 20a). 
Overlapping Valleys with a Jaccard Index ≥ 0.6 were 1,379/1,560 (~88%), which 
represented about the 80% of both total Zinc-treated and Untreated Valleys (Figure 20b). 
 
 
 
 
 
 Figure 20. Overlapping Valleys in Zinc -treated and Untreated conditions 
 a) Venn Diagram showing the high degree of overlap (~91%) between Valleys found in Zinc-treated and 
Untreated conditions; b) Even if Venn Diagram showing the high degree of overlap (~91%) between Valleys 
found in Zinc-treated and Untreated conditions; 
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Students’ t-test, performed to measure statistical significance, revealed the presence of: 
 536 LtoE-shifted Valleys 
 414 EtoL-shifted Valleys 
 429 Stable Valleys 
Notably, while we observed a comparable number of Stable, LtoE- or EtoL-shifted 
Valleys, the distribution of their Diff_S50 values was clearly different (Figure 21), with 
LtoE-shifted Valleys showing a broader dispersion than the EtoL-shifted Valleys which, 
instead, showed Diff_S50 values generally closer to zero. 
 
 
 
 
Figure 21 - Distribution of Diff_S50 values in LtoE shifted, Stable and EtoL shifted 
Valleys.  
These overlaid histograms show the distribution of Diff_S50 values in LtoE shifted (red histogram), Stable 
(orange histogram) and EtoL shiftedValleys (grey histogram). 
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ROC Curve and assessment of performance 
 
To assess the performance goodness of our DART pipeline, we performed a ROC curve 
analysis.  
A ROC (Receiver Operating Characteristic) curve is usually employed to predict the 
robustness of diagnostic tests; on the typical ROC graph, each point represents a ratio 
between sensitivity and specificity (Zweig and Campbell, 1993) of the predictions.  
The robustness of a ROC curve is measured by the Area Under the Curve (AUC), with 
values ranging between 0 and 1, representing the accuracy of the method being tested. 
Intervals of AUC values correspond to specific test evaluation, as follows: 
 0.0 - 0.6 = Failed 
 0.6 - 0.7 = Poor 
 0.7 - 0.8 = Fair 
 0.8 - 0.9 = Good 
 0.9 - 1.0 = Excellent 
To perform the ROC analysis using our pipeline, we randomly took a set of replicating 
regions by visually inspecting and comparing raw profile signals of Zinc-treated and 
Untreated Repli-Seq BrdU samples in the Genome Browser. We identified 115 regions to 
use as control dataset, 57 of which showing clear differences in Replication Timing 
(positive controls – all LtoE-shifted) and 58 showing a stable Replication Timing upon 
treatment with Zinc (Figure 22). 
Notably, while we easily recognized Valleys with a clear LtoE shift of the Replication 
Timing, none of the EtoL shifted valleys were obviously identifiable, either because they 
do not exist or, more likely, because the difference in Replication Timing was too small. 
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Indeed, as shown in Figure 21, EtoL shifted Valleys had Diff_S50s generally closer to 
zero, making therefore the identification by eye extremely difficult. 
However, the analysis returned an AUC of ~0.95, thus indicating an excellent predictive 
power of the DART pipeline. The ROC curve is reported in Figure 23. 
 
 
 
 
Figure 22 - Example of Control Regions used for the computation of the ROC Curve.  
In this picture it is shown an example of regions used as controls for the computation of the ROC Curve. 
Blue tracks: Zinc-treated Repli-seq S-phase fractions; Emerald tracks:  Untreated Repli-seq S-phase 
fractions; Cyan dotted lines: Zinc-treated Repli-seq Inverted-Vs; Green dotted lines: Untreated Repli-seq 
Inverted-Vs; Green squares: Negative control regions retrieved as Inverted V-s starting replication at the 
same S-phase fraction between Zinc-treated and Untreated conditions; Red squares: Positive control regions 
retrieved as Inverted V-s starting replication at different S-phase fraction between Zinc-treated and Untreated 
conditions (LtoE shif of Replication Timing) 
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Diff_S50 values as a proxy for deregulation of 
Replication Timing 
 
We took advantage of the ROC curve to estimate the Diff_S50 threshold that guaranteed 
the best trade-off between specificity and sensitivity for the call of stably- or differentially-
replicated regions following PML-RARα expression.   
The Diff_S50 cut-off value for the LtoE shifted regions was equal to -0.025, corresponding 
to specificity and sensitivity scores of 0.88 and 0.95, respectively.  
Due to the lack of recognisable positive controls showing a EtoL of Replication Timing, 
we could not compute a Diff_S50 cut-off value for the EtoL shifted regions; therefore, we 
applied the same value (suitably changed in sign) as threshold for both LtoE- and EtoL-
shifted Valleys, although we knew it would have been very stringent for the latter. We 
called this value Differential Replication Threshold, DRT. 
Furthermore, due to its relevance for our following analyses, we also calculated the 
threshold for Valleys that did not show any significant change in their Replication Timing 
(Stable Replication Threshold, SRT).  
The SRT, corresponding to a specificity value close to the sensitivity of the DRT (0.95), 
and a sensitivity value close to the specificity of the DRT (0.825), was equal to 0.0096 
(Table 4, Figure 23). 
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Threshold Diff_S50 
(absolute value) Specificity Sensitivity 
Differential Replication Threshold 0.025 0.88 0.95 
Stable Replication Threshold 0.0096 0.95 0.825 
Table4 –  DRT and SRT with related Diff_S50 values, sensitivity and specificity of DRT 
and SRT 
 
Figure 23. ROC Curve, DRT and SRT 
ROC Curve assessing the robustness of the DART pipeline. Each point in the curve represent a 
Sensitivity/Specificity ratio. 
Red triangle: Sensitivity/Specificity ratio chosen for DRT, equal to a Diff_S50 Value of 0.0252405 
Orange Circle: Sensitivity/Specificity ratio chosen for SRT, equal to a Diff_S50 Value of 0.00961271 
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Differentially Replicating Valleys  
 
Using the DRT and SRT thresholds, we refined the subsets of relevant Valleys, obtaining 
1,074 Valleys classified as follows: 
440 LtoE-shifted Valleys with: 1) a significant difference in S50 values between Zinc-
treated and Untreated Samples and 2) a Diff_S50 value smaller or equal to the negative 
value of the DRT identified by the ROC curve; 
183 EtoL-shifted Valleys with: 1) a significant difference in S50 values between Zinc-
treated and Untreated Samples, and 2) a Diff_S50 value higher or equal to the positive 
value of the DRT identified by the ROC curve; 
451 Stable Valleys without significant difference in S50 values between Zinc-treated and 
Untreated Samples, or with a Diff_S50 value higher than the positive, and smaller than the 
negative, absolute value of the SRT identified by the ROC curve. 
 
In summary, our genome-wide analysis identified 1,717 and 1,707 Valleys for Zinc-treated 
and Control samples, respectively, covering about 14% of the human genome.  
After the application of the DRT and SRT threshold, we obtained 1,074 Valleys, covering 
approximately 9% of the genome, of which: 3.8% (n=451 Valleys) showed a stable 
Replication Timing, 3.7% (n=440 Valleys) and 1.5% (n=183 Valleys) showed, 
respectively, a late-to-early and an early-to-late shift of Replication Timing following 
PML-RARα expression. 
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Validation of DART pipeline 
To test the reproducibility of the results obtained in our experimental data, we applied the 
pipeline to a biological replicate of the Repli-seq experiment (from now on referred as 
“Replicate #2”). 
1,730 and 1,748 Valleys were identified in the Zinc-treated and Untreated sample, 
respectively (Table 5), with a high degree of overlap with the Valleys identified in the first 
experiment (Figure 24): ~84% (n=1,243/1,482) of the Valleys identified in the two 
Untreated replicates and ~83% (n=1,266/1,520) of those identified in the two Zinc-treated 
replicates overlapped for at least 80% of their length (i.e., four intervals of 50 kb out of 
five). We interpreted this result as the consequence of the reproducibility of the 
experimental procedure and of the robustness of the bioinformatic pipeline. 
 
 
 
Zinc-treated Valleys Untreated Valleys 
Replicate 1 1,717 1,707 
Replicate 2 1,730 1,748 
Table 5. Valleys identified in the Experiment1 and in the Replicate  #2 
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Figure 24 - Overlap between Valleys in Zinc-treated and Untreated Samples in 
Replicate1 and Replicate#2.  
Both replicates show a reciprocal overlap of more than 80%, for both Zinc-treated and Untreated condition, 
as shown by the Venn Diagrams above.  
 
 
Next, we computed a ROC curve using the same visually identified control regions used 
for the Replicate #1; 50/57 positive controls and 52/58 negative controls were found to 
overlap with the Valleys of Replicate #2. 
The AUC of Replicate #2 was equal to ~0.8, lower than the original one, but still scoring a 
good predictive power. 
DRT and SRT were obtained with a sensitivity of 0.77 and 0.73, respectively, and a 
specificity of 0.70 and 0.76, as summarized in Table 6. 
 
 
 
 
 
 Table 6. Comparison of DRTs and SRTs and corresponding sensitivity and specificity 
values, in Replicate1 and Replicate2.  
 
 
 
Replicate2 
  
 Replicate1 
  
 
Threshold 
Diff_S50 
Specifi
city 
Sensitivity 
Threshold 
Diff_S50 
Specifi
city 
Sensiti
vity 
DRT 0.0205851 0.7 0.77 0.0254205 0.88 0.95 
SRT 0.00855118 0.76 0.73 0.00961271 0.95 0.825 
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Thus, applying the DRT and SRT for Replicate #2 we found: 
 417 LtoE-shifted Valleys  
 153 EtoL-shifted Valleys 
 673 Stable Valleys 
Comparison of Valleys identified in the two replicates, we observed different levels of 
overlap in the three different classes, ranging from 47-44% in the LtoE- to 20-17% in 
EtoL-shifted Valleys (Figure 25). 
 
 
Figure 25. Overlap of DRVs and Stable Valleys between Replicate#1 and Replicate#2.  
The Venn Diagrams show the mutual overlap among class of Valley in Replicate#1 and Replicate#2.  
Red: LtoE-shifted Valleys; Grey: EtoL-shiftedValleys. 
 
 
Given i) the complexity of the experimental procedure being studied and ii) the high 
stringency we applied to the analyses, we considered this overlap a good sign of 
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consistency and hence we decided to proceeded with the characterization of the 
differentially-replicated regions identified in Replicate #1. 
Characterization of Differentially Replicating Valleys 
 
Differences in Replication timing after PML-RARα expression are 
not evenly distributed throughout the genome but occur 
preferentially in regions replicated in specific timing of the S-phase. 
 
As a first approach to the characterization of the Differentially Replicating Valleys, we 
studied whether differences in Replication Timing were uniformly distributed throughout 
the S-phase or were concentrated in some particular S-phase fractions. 
At this purpose, we first transformed each of the six consecutive gates used during the cell 
sorting (and based on DNA content) into a specific range of S50 values (S1-S6; Table 7). 
The lowest S50 value among the five S50 values of the 50 kb windows that constitute each 
single Valley was then used to call each Valley as “Sn Valley” (where Sn is “S1” to “S6”), 
if its minimum S50 value fell within the range corresponding to that particular Sn. The 
distribution of replication timing (S50) of the three classes of Valleys (i.e., EtoL, LtoE or 
Stable) was finally studied in Zinc-treated and Untreated cells (Figure 26).  
 
 81 
 
 
S50 interval S sub-phase  
0<= S50 <0.145 S1 
0.145<= S50 <0.3050 S2 
0.3050<= S50 <0.47 S3 
0.47<= S50 <0.6375 S4 
0.6375<= S50 <0.84 S5 
0.84<= S50 <=1 S6 
Table 7. Re-association of S50 interval to S sub-phases 
 
As clearly shown in Figure 26, LtoE shifts of Replication Timing, globally, took part in 
Middle-S phase. Indeed, whereas in Untreated cells the higher number of Valleys was 
found in Middle-S phase (S3-S4), after PML-RARα induction we observed a general shift 
of Replication Timing toward earlier S-phase fractions, with a peak of replicating Valleys 
in Early/Middle-S phase (S2-S3).  
Conversely, EtoL shifts of Replication Timing mostly involved regions replicated very 
early in the S-phase, with Valleys shifting from S1 in Untreated cells to S2 following 
PML-RARα expression. In addition, while LtoE shifts arose in Middle S-phase and 
persisted until late-S phase, EtoL occurrences were mostly confined in S1 and S2 sub-
phases. 
We then concentrated on LtoE- and EtoL-shifted Valleys, and observed that changes in 
replication timing did not necessarily resulted in a net shift from one S-phase fraction to 
another. To appreciate to what extent LtoE- or EtoL shifts (both within the same, or 
between different S-phase fractions) were distributed throughout the S-phase, we 
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constructed a square matrix in which it is shown the S-phase fraction in which each Valley 
showing a significant change of replication timing, was replicated before and after PML-
RARα expression. A separate matrix was built for LtoE and EtoL shifts. 
As shown in Figure 27, LtoE and EtoL shifts took place in Early/Middle-S phase and 
Early-S phase, respectively; however, most of changes in Replication Timing occurred 
within the same S-phase fraction (~62% and ~49% for LtoE- and EtoL-shifted Valleys, 
respectively). 
 
 
Figure 26 –  Shift of Replication Timing in LtoE shifted and EtoL shiftedValleys.  
DRVs replicating in different S -phase fractions after induction by Zinc; Right panel: S50 
values in DRVs before and after expression of PML -RARα  
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Figure 27 - Differences in Replication Timing in LtoE shifted (green) and EtoL 
shifted(red) Valleys  
Two heatmaps showing the percentage of those LtoE-shifted Valleys (left) and EtoL-shiftedValleys (right) 
replicating in different S-phase fractions and those replicating in the same S-phase fraction. 
Heatmap was obtained by calculating, for each Valley, the S-phase in which they replicated before and after 
expression of PML-RARα and successively plotting the percentage of Valleys being replicated in each S sub-
phase before and after induction by Zinc. 
 
Overall, these data suggest that the Valleys showing changes in Replication Timing 
following PML-RARα expression, are not uniformly replicated during the S-phase: LtoE-
shifted Valleys are normally replicated mainly during Early/Middle or Middle-S phase, 
while the EtoL-shifted ones are normally replicated almost exclusively during very Early-S 
phase.  
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EtoL shifted Valleys are enriched for PML-RARα binding sites 
 
We then asked whether PML-RARα binds to the DRVs, using ChIP-seq experiments 
performed in the same U937PR9 cellular system.   
Anti-PML ChIP-seq experiments in Zinc-treated (t=8h) and Untreated U937PR9 cells were 
analysed as explained in “Materials and Methods”. Anti-PML antibodies did not recognize 
any enriched site or “peak” in Control cells, arguing against a direct DNA-binding activity 
of the endogenous PML protein. In the Zinc-treated samples, instead, we found ~23,600 
peaks corresponding to bona fide PML-RARα binding sites (Martens et al., 2010; Wang et 
al., 2010). 
Analysis of the distribution of PML-RARα peaks within the DRVs showed that EtoL-
shifted Valleys were significantly enriched for PML-RARα binding sites when compared 
to Stable Valleys (about 9.0 and 5.6 binding sites on average per Valley, respectively); 
conversely, LtoE-shifted Valleys were significantly depleted (about 2.5 binding sites per 
Valley) (Figure 28, Table 8). Statistical significance was tested by a Mann-Whitney test. 
 
N. PML-RARα peaks in Valleys   
1,091 LtoE shifted Valleys (440) 
2,548 Stable Valleys (451) 
1,654 EtoL shifted Valleys (183) 
Table 8. Number of PML-RARα peaks in the three categories of Valleys  
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Figure 28 -  Statistical signif icance for enrichment of PML-RARα binding sites in 
Valleys.  
Results of Mann-Whitney statistical significance for depletion or enrichment of PML-RARα binding sites are 
represented by barplots.  
Significance is expressed as -log10(p-value). From left to right: comparison of PML-RARα peaks in Valleys 
between LtoE shifted and EtoL shiftedValleys, between EtoL shifted and Stable Valleys and, finally, 
between LtoE shifted and EtoL shifted Valleys. 
 
 
 
 
 
 
 86 
 
The distribution of gene expression level in regions with Different 
Replication Timing mirrors the distribution of Replication Timing 
and their changes through the S-phase 
 
 
Several studies (Dellino et al., 2013; Fraser, 2013; Huvet et al., 2007; Méchali, 2010; 
Miotto et al., 2016; Rivera-Mulia et al., 2015) revealed a strict correlation between 
Replication Timing and transcription, showing that intense transcriptional activity 
positively correlates with early replication timing. 
We thus investigated the relationship between basal transcription levels, or transcription 
regulation imposed by PML-RARα few hours after its expression (at t=8 hours), and the 
observed changes of replication timing observed 16 hours later (at t=24 hours).  
For this purpose, we took advantage of RNA-seq experiments carried out in control 
U937PR9 cells and 8 hours after PML-RARα induction, and performed Differential 
Expression (DE) analyses according to standard procedures and computed by a custom 
pipeline (see Materials and Methods for details). 
Henceforth, we mapped expressed genes within the DRVs and calculated their average 
expression (measured as Transcripts per Million, TPM) in each Valley; finally, for each S-
phase fraction in the Control condition, we studied, for each class of Valleys, the 
distribution of the expression levels before and after the expression of PML-RARα (Figure 
29).  
Thus, we found that the distributions of gene expression of the three classes of Valleys was 
significantly different, with Stable Valleys containing highly expressed genes in early-S, 
EtoL-shifted Valleys in very early-S and LtoE-shifted Valleys in middle-S phase. 
Furthermore, in LtoE-shifted Valleys we found a significant increase of TPM distribution 
in S3 (Figure 29, boxplots), consistent with the shift in Replication Timing in 
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Differentially Replicating Valleys, (which, in Control condition took place in Valleys 
replicating in S3-S4 S sub-phases), as previously depicted in Figure 26.  
On the other hand, in EtoL shifted Valleys we observed a significant decrease in TPM 
distributions in Early-S fractions (S1-S2), consistent with the EtoL shift of Replication 
Timing found in the same S-phase fractions (for comparison, Figure 26). 
At the same time, no significant variations in TPM distributions were found in Stable 
Valleys, thus confirming that a different level of expression was coherent with a different 
Replication Timing in LtoE- and EtoL-shifted Valleys. 
Together, these results suggest that transcription levels measured at early time points (t=8 
hours after PML-RARα induction) might contribute to the changes of replication timing 
observed 16 hours later (at t=24h). 
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Figure 29 - DRVs are characterized by different levels of expression throughout the S -
phase and differences in expression levels after induction of  PML-RARα mirror 
changes in Replication timing . 
EtoL-, LtoE-shifted and Stable Valleys differ for expression levels in the various S-phase fractions. 
Transcriptional levels in Untreated Cells (green lines ) change after induction of PML-RARα (blue lines). 
Differences in  expression (boxplots) were statistically tested by the mean of a Mann-Whitney test. 
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Differentially Replicated Valleys are enriched for direct PML-RARα 
target genes 
 
Combining the identified PML-RAR binding sites and gene expression at Stable, EtoL- or 
LtoE-shifted Valleys, we then investigated the relationship between changes of replication 
timing and transcriptional regulation following PML-RARα induction. 
As previously observed (Alcalay et al., 2003; Gaillard et al., 2015a), our RNA-seq 
experiments showed that PML-RARα induces both gene down-regulation and up-
regulation (n=2,503 and 1,962 genes, respectively). A concise summary of RNA-seq 
experiment results is shown in Table 9. 
 
 
 
 
 
    
Table 9 - Expressed and regulated genes before and after induction by Zinc   
Genes were considered expressed if TPM>=0.8 and regulated if adjusted p-value was equal to or higher than 
0.2 and either the Untreated or the Zinc-treated sample had an expression equal to or higher to 0.8 TPM 
 
              
In order to investigate whether, following PML-RARα induction, DRVs were enriched for 
regulated genes compared to Stable Valleys, we counted the fraction of up- and down-
regulated genes and compared them to the total number of expressed genes falling into 
Differentially Replicating or Stable Valleys. 
We found that the LtoE-shifted Valleys showed a two-fold enrichment of up-regulated 
genes compared to Stable Valleys: ~26% (n=169/644 genes) in LtoE-shifted versus ~14% 
(n=150/1,031 genes) in Stable Valleys, and a two-fold depletion of down-regulated genes: 
~8% (n=50/644) in LtoE-shifted versus ~14% (n=146/1,031) in Stable Valleys (Table 10).  
 
Expressed and regulated genes  
before and after expression of PML-RARα 
Expressed 
Untreated 
Expressed 
after Zinc 
treatment 
(8h) 
Total 
deregulate
d 
Up-
regulated 
Down-
regulated 
10,671 10,805 4,465 1,962 2,503 
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The opposite behaviour was observed for the EtoL-shifted Valleys, which were 
significantly enriched for down-regulated genes:  ~40% (n=237/600) in EtoL-shifted vs. 
~14% (n=146/1,031) in Stable Valleys, and depleted for up-regulated genes: ~4% 
(n=23/600) in EtoL-shifted vs. ~14%, (n=150/1,031) in Stable Valleys. (Table 10 and 
Figure 30).  
Interestingly, also the proportion of up-regulated genes vs. down-regulated genes in the 
different classes of Valleys showing altered replication timing, follows the same 
behaviour: up-regulated genes in LtoE-shifted Valleys were 77%, and down-regulated 
genes in EtoL shifted Valleys were 91% of the total deregulated genes (Table 10). 
 
Valleys Deregulated genes Number 
% of DeReg 
genes on Total 
DeReg genes 
Number of 
Total 
expressed 
genes 
% of DeReg 
genes on Total 
expressed 
genes 
LtoE_shifted 
Up-regulated 169 77.2 
644 
26.2 
Down-regulated 50 22.8 7.8 
Total 219   34.0 
Stable 
Up-regulated 150 50.7 
1,031 
14.5 
Down-regulated 146 49.3 14.2 
Total 296   28.7 
EtoL_shifted 
Up-regulated 23 8.8 
600 
3.8 
Down-regulated 237 91.2 39.5 
Total 260   43.3 
Table 10 - Number of Up- and Down- regulated genes on the total number of expressed 
and total deregulated genes in DRVs  
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Figure 30 - Enrichment and depletion study for Up- and Down-regulated genes in DRVs 
Results of Chi-square statistical significance for depletion or enrichment of deregulated genes in Valleys are 
represented as barplots. Significance is expressed as -log10(p-value). From left to right: comparison of up- 
(left panel) and down-regulated genes (right panel) in Valleys between “LtoE shifted versus Stable Valleys”, 
“EtoL shifted versus Stable Valleys” and, finally, between “LtoE shifted versus EtoL shifted Valleys”. 
 
 
Next, we asked: 1) how many PML-RARα peaks were found on deregulated genes within 
Valleys, 2) how many of the deregulated genes were direct targets of PML-RARα (defined 
as genes showing PML-RARα bound either to their promoter or to gene body), and 3) how 
many of the direct target genes showed PML-RARα peaks at their promoter. 
 
In total, we found 1,654, 2,548, and 1,091 PML-RARα peaks in EtoL-, LtoE-shifted and 
Stable Valleys, respectively. Interestingly, the vast majority of the 302 PML-RARα peaks 
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mapping at deregulated genes in LtoE-shifted Valleys bound to up-regulated genes: ~82% 
(n=247/302) vs. ~18% (n=55/302) at up- and down-regulated genes, respectively.  
On the other hand, EtoL-shifted Valleys were enriched for PML-RARα peaks at down-
regulated genes: ~95% (n=452/478) of the 478 peaks which were annotated to deregulated 
genes in EtoL-shifted Valleys, were bound to down-regulated genes and only ~5% 
(n=26/478) to up-regulated ones (Table 11, Figure 31).  
In Stable Valleys, instead, PML-RARα showed no preferential binding, with ~46% 
(n=260/569) and ~54% (n=309/569) peaks annotated on, respectively, up- and down-
regulated genes.  
Such differences were evaluated by a Chi-square test, and were statistically significant 
when compared to Stable Valleys, or by comparing LtoE- versus EtoL-shifted Valleys 
(Figure 32). 
 
Valleys PML-RAR peaks number 
% of PML-
RARa peaks 
on DeReg 
genes 
Number 
of Total 
PML-
RAR 
peaks 
% of PML-
RARa peaks 
on Total 
LtoE_shifted 
on Up-regulated 
genes 
247 
81.8 
1,091 
22.6 
on Down-
regulated genes 55 18.2 5.0 
Total 302   27.7 
Stable 
on Up-regulated 
genes 
260 
45.7 
2,458 
10.6 
on Down-
regulated genes 
309 
54.3 12.6 
Total 569   23.1 
EtoL_shifted 
on Up-regulated 
genes 26 5.4 
1,654 
1.6 
on Down-
regulated genes 452 94.6 27.3 
Total 478   28.9 
Table 11 - The table summarized the proportions of PML-RARα peaks annotated on 
Up- and Down-regulated genes on the total number of PML-RARα peaks observed in 
the three classes of Replication Valleys.  
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Figure 31 - Locations of PML-RARα peaks on deregulated genes in Stable and DRVs.  
The barplot illustrates the percentages of PML-RARα peaks found in UP- and DOWN-regulated genes by 
class of Stable and Differently Replicated Valleys; sub-groups of peaks that map or not to gene promoters are 
also shown.  
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Figure 32 –  Enrichment and depletion for PML-RARα peaks mapped on deregulated 
genes in DRVs  
Results of chi-square statistical significance for depletion or enrichment of peaks on deregulated genes in 
Valleys are represented as barplots. Significance is expressed as -log10(p-value). From left to right: 
comparison of PML-RARα binding sites on up- (left panel) and down-regulated genes (right panel).  
Comparisons were performed as “LtoE shifted versus Stable Valleys”, “EtoL shifted versus Stable Valleys” 
and, finally, “LtoE shifted versus EtoL shifted Valleys”. 
 
 
 
 
 
Moreover, we found that, both in LtoE- and EtoL-shifted Valleys, PML-RARα 
preferentially bound to gene promoters (± 1 kb from TSS) of down-regulated genes 
compared to up-regulated genes: ~65% vs 30% and ~42% vs ~19% in LtoE- and EtoL-
shifted Valleys, respectively, as shown in Table 12 and Figure 31. 
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Valleys PML-RAR peaks number 
% of PML-
RARa 
peaks on 
DeReg 
genes 
Number of 
Total PML-
RAR peaks 
% of PML-
RARa 
peaks on 
Total 
LtoE_shifted 
on Up-regulated genes 247 81.8 
1,091 
22.6 
on Down-regulated genes 55 18.2 5.0 
Total 302   27.7 
Stable 
on Up-regulated genes 260 45.7 
2,458 
10.6 
on Down-regulated genes 309 54.3 12.6 
Total 569   23.1 
EtoL_shifted 
on Up-regulated genes 26 5.4 
1,654 
1.6 
on Down-regulated genes 452 94.6 27.3 
Total 478   28.9 
 Table 12. Proportion of PML-RARα peaks on promoter of deregulated genes in DRVs . 
 
 
 
Considering the deregulated genes falling in EtoL-shifted Valleys, we found that the most 
of the down-regulated genes (n=211/237, ~89%) were bound by PML-RARα; in an 
opposite fashion, the proportion of the up-regulated that were also bound by PML-RARα 
was smaller (n=11/23, ~48%).  
On the other hand, in LtoE-shifted Valleys, up-regulated (n=102/169, ~60%) and down-
regulated genes (n=36/50, ~72%) were directly bound by PML-RARα in comparable 
proportions (Table 13).  
Though, when studying the location of PML-RARα binding sites within the genes, we 
found that, considering the proportion of deregulated genes with at least one peak of PML-
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RARα on promoter compared the total deregulated genes, we observed that down-
regulated genes were mostly bound on promoters of down-regulated genes (LtoE: n=33/50, 
~66%; EtoL: n=176/237, ~74%) than the up-regulated ones (LtoE: n=63/169, ~37%; EtoL: 
n=5/23, ~22%), in both DRVs;  
On the other hand, if we evaluated the number of genes with a PML-RARα binding site on 
promoter out of the number of  genes with at least one peak of PML-RARα, wherever 
located in the locus, we noticed that nearly all of the down-regulated genes are bound on 
promoters, in both LtoE- shifted- (n=33/36, ~92%) and EtoL-shifted Valleys (n=176/211, 
~83%). In addition, a lower fraction of up-regulated genes, whereas definitively not 
negligible, presented a PML-RARα binding site on their promoters (n=63/102, ~62% and 
n=5/11, ~46%) in both LtoE- and EtoL-shifted Valleys, respectively (Table 13). 
 
 
Valleys 
Deregulated 
genes 
Tot 
Number 
Number  
of 
DeReg 
genes 
bound 
by PML-
RARa 
%  DeReg 
genes 
bound by 
PML-RARa 
/ Total 
DeReg 
genes 
Number  
of DeReg 
genes 
bound by 
PML-RARa 
on 
promoter 
%  DeReg 
genes 
bound on 
promoter 
by PML-
RARa / 
bound by 
PML-
RARa  
%  DeReg 
genes 
bound on 
promoter 
by PML-
RARa / 
Total 
DeReg 
genes 
LtoE  
shifted 
Up-regulated 169 102 60.4 63 61.8 37.3 
Down-regulated 50 36 72.0 33 91.7 66.0 
EtoL 
shifted 
Up-regulated 23 11 47.8 5 45.5 21.7 
Down-regulated 237 211 89.0 176 83.4 74.3 
Table 13. Up-Regulated and Down-regulated PML-RARα direct targets.  
 
Overall these results suggest that the two opposite phenotypes of Replication Timing 
observed after the ectopic expression of PML-RARα (i.e. EtoL and LtoE shifts of the 
Replication Timing) might have different mechanistic links. 
In EtoL-shifted regions PML-RARα exerts its function by mainly down-regulating its 
target genes, binding nearly always at their promoters. In addition, in these Valleys it is 
also possible to appreciate some promoter-bound up-regulated genes that, though, being in 
 97 
 
much lower number than the down-regulated ones, are probably not able to give a 
contribution to the deregulation of such genomic regions.  
Differently, in regions showing a LtoE shift of Replication Timing, PML-RARα seems to 
act in a dual manner: i) eliciting the down-regulation of few targets, again directly binding 
onto their promoters (such as for the down-regulated genes in EtoL-shifted regions) and ii) 
increasing the expression of several specific genes, either through binding to their 
promoters or to regulatory sites located in the gene bodies (e.g enhancer or both mapped 
and unmapped alternative TSSs). 
 
PML-RARα plays a direct role in the deregulation of processes 
fundamental for oncogenic transformation in both LtoE- and EtoL-
shifted Valleys 
 
To better portrait the deregulative role of the oncogene on normal Replication Timing, we 
performed two Gene Ontology (GO) analyses by taking advantage of the gene list 
enrichment analysis tool EnrichR (GO database: “GO_Biological_Process_2015”) (Chen 
et al., 2013). One analysis was performed by taking into consideration all PML-RARα 
target genes in Differentially Replicating Valleys whereas in the other one we focused only 
on direct targets. Both analyses were performed separately for deregulated LtoE- and 
EtoL-shifted Valleys 
Interestingly for us, we noticed that both in LtoE- and EtoL-shifted Valleys (Tables 14 and 
15) the majority of the top ten biological processes (adjusted p-value <=0.005) involving 
deregulated genes were enriched also in the analysis performed only on direct PML-RARα 
targets, thus suggesting that PML-RARα might impact these processes through both direct 
and indirect mechanisms. Moreover, depending if in LtoE- or EtoL-shifted Valleys, PML-
RARα seems to enhance or suppress processes being already known as often deregulated 
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in cancer, and particularly in leukemia, such as autophagy, glucose metabolism, cell ageing 
in LtoE-shifted Valleys and myeloid cell differentiation and regulation of telomere 
maintenance in EtoL-Shifted Valleys. 
Table 14 –  GO terms enriched for deregulated genes in LtoE-shifted Valleys.  
Deregulated genes in LtoE-shifted Valleys are enriched in GO terms relative to cell survival 
and adaptation. In red, GO terms being enriched also in the direct PML-RARα target genes  
GO analysis  (Adjusted pvalue <=0.05). In bold: direct PML-RARα target genes  
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Table 15 –  GO terms enriched for deregulated genes in EtoL-shifted Valleys.  
Deregulated genes in EtoL-shifted Valleys are enriched in GO ter ms relative to cell survival 
and adaptation. In red, GO terms being enriched also in the direct PML -RARα target genes 
GO analysis (Adjusted pvalue <=0.05). In bold: direct PML -RARα target genes  
 
A different pre-existing chromatin asset characterizes the three 
classes of Replication Valleys 
 
 PML-RARα induces transcription repression of its target genes by inducing chromatin 
remodelling  through recruitment of chromatin modifiers, such as DNA methylases and 
histone deacetylases directly to PML-RARα - bound sites (Croce et al., 2002; Grignani et 
al., 1998; Hoemme et al., 2008; Saeed et al., 2011; Villa et al., 2007). 
To study how pre-existing chromatin structure is involved in the observed changes of 
replication timing describing above, anti-H3K4me3, anti-H3K4me1 and anti-H3K27Ac 
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ChIP-seq experiments were performed in Zinc-treated (t=8 hours) and Untreated U937PR9 
cells (t=0 hour).  
For each ChIP-seq experiment, we first calculated the normalized coverage (measured as 
the number of reads in each Valley divided by the total number of reads of each 
experiment) of the three histone marks within each Differentially Replicating Valley, and 
then compared the signal intensities.  
As showed in Figure 33, we found that before induction of the PML-RARα expression, 
there were significant differences in the distribution of the three histone marks compared to 
Stable Valleys, with LtoE-shifted ones showing lower levels for all tested histone 
modifications and EtoL-shifted Valleys showing significantly higher signal intensities. 
Altogether, these observations suggest that the pre-existing chromatin status within DRVs 
plays a role in the observed behaviour following PML-RARα induction.  
 
 
Expression of PML-RARα significantly changes chromatin status in 
Differentially Replicating Valleys  
 
We finally compared the signal intensity of the three histone-modifications (H3K4me3, 
H3K4me1 and H3K27Ac), before and after PML-RARα induction, at Stable and 
Differentially Replicating Valleys, by analysing ChIP-seq experiments performed in Zinc-
treated (t=8 hours) and Untreated U937PR9 cells (t=0 hour). Although negligible 
compared to the differences among the three classes of Valleys in the signal distributions 
prior to PML-RAR induction (as discussed above), we observed for all the histone marks 
significant differences in distribution of coverage within both Differentially Replicating 
and Stable Valleys after PML-RARα induction (Figure 33). 
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Figure 33 - Distribution of H3K4me3 (left), H3K4me1 (centre) and H3K27Ac (right) 
normalized coverage before (“NT”) and after (“ZN”) expression PML -RARα in DRVs.  
Differences between distributions were tested by the mean of a Mann-Whitney test. P-values are reported for 
each comparison.  
 
 
We also compared the extent of these differences in all the three classes of Valleys, by 
measuring changes in signal intensity following PML-RARα inductions as log2ratio 
between the normalized coverages measured in the Zinc-treated cells vs. the Untreated 
ones, and statistical significance was assessed by the mean of a Mann-Whitney test (Figure 
34).  
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While a slight decreased of H3K4me1 signal was observed for all the three classes of 
DRVs, with no significant differences among them, changes in H3K4me3 and H3K27Ac 
levels revealed strong differences. In particular, LtoE-shifted Valleys showed a dramatic 
increase of both histone modifications when compared to Stable and EtoL-shifted Valleys, 
while the latter displayed significant decrease in H3K4me3 and H3K27Ac signals when 
compared to LtoE and Stable Valleys (Figure 34). 
In summary, the last data show that, among the three classes of Valleys, the EtoL-shifted 
ones are chacterized, at basal level, by the highest levels of mono- and tri-methylated 
H3K4, and acetylated H3K27, all generally associated with open, transcriptionally active 
chromatin; LtoE-shifted Valleys, instead, are characterized by the lowest levels of the three 
histone modifications.  
Following PML-RARα induction, to some, but significant, extent, EtoL-shifted Valleys 
show decreased H3K4me3 and H3K27ac signals, while LtoE-shifted Valleys show 
increased signals of both histone marks.  
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Figure 34 - Distributions of differences in coverage for H3K4me3 (left), H3K4me1 
(centre) and H3K27Ac (right).  
Differences for normalized coverage were calculated as log2(CoverageZinc/CoverageUntreated) in each DRV and 
differences for log2ratio were tested for significance among Valleys by the mean of a Mann-Whitney test. P-
values are reported for each test. 
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DISCUSSION 
 
DART is an excellent predictive method, comparing two 
Repli-seq experiments, to identify genomic regions that 
have undergone a change in the Replication Timing 
 
Repli-seq (Hansen et al., 2010a)  is one of the main techniques employed to study the 
dynamics of  of DNA Replication. It allows to study the progression of DNA replication 
both in space and time (i.e. when, during the S phase (time), each specific region of the 
genome (space) is replicated). 
However, up to now, all current studies that used Repli-seq, have analysed Replication 
Timing in one specific experimental condition, or have compared Repli-seq data with other 
methodologies (Barlow et al., 2013; Chen et al., 2010; Debatisse et al., 2012; Dellino et al., 
2013a; Hansen et al., 2010a; Liu et al., 2015; Polak et al., 2015; Pope et al., 2014).  
There are no studies, to our knowledge, that use Repli-seq experiments to measure 
genome-wide differences in Replication Timing between different cell lines, or 
experimental conditions in the same cell context, and test their statistically significance. 
In this work, we developed a bioinformatic method that, comparing two different 
experimental conditions, allows the identification of genomic regions showing statistically 
significant differences in their Replication Timing. 
The method, named DART (Differential Analysis of Replication Timing), is a 
bioinformatic pipeline which, starting from the Repli-seq experiments from two 
experimental conditions (or cell types), applies a series of manipulations to the data 
(normalization, scaling, transformation, etc) to measure the Replication Timing for each 
experimental condition or cell types (i.e., the S50 value) that can be visualized as a S50 
 105 
 
profile in a Genome Browser and, more importantly, provides a list of genomic regions, 
enriched in DNA replication origins, showing statistically significant differences in 
Replication Timing.  
Examining the predictive power of our method, we performed a ROC Curve analysis 
(Zweig and Campbell, 1993) using a control dataset of regions showing different 
Replication Timing, obtained by visual inspection of Repli-seq experiments on the UCSC 
Genome Browser.  
We obtained an AUC equal to 0.95, which demonstrates an excellent predictive robustness 
of our method in identifying genomic regions that have undergone a change in the 
Replication Timing between two experimental conditions. 
 
The identification of this bioinformatic procedure was used to ask whether and where an 
oncogene (we used PML-RAR, as prototype) regulates the timing of the DNA 
replication. We then characterized these differently replicated regions, by integrating 
Repli-seq with RNA-seq and ChIP-sequencing experiments. 
For this study, we used the U937 cells as model system, a promonocytic cell line 
transduced with a vector carrying the PML-RARα cDNA under control of the inducible 
mouse metallothionein 1 (MT-1) promoter. The PR9 clone, used here and in several other 
publications to characterize the tumour initiation properties of PML-RAR expresses the 
oncogene at levels comparable to the ones of APL fresh blasts, when induced with100 mM 
of Zinc. 
Therefore, we applied DART to study changes in Replication Timing in U937PR9 cells 
before and after the expression of PML-RARα. 
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Expression of PML- RARα induces specific changes in 
normal Replication Timing 
 
Different studies have shown a positive correlation between transcription and regions 
enriched for ORIs (Dellino et al., 2013; Martin et al., 2011; Mesner et al., 2011; Miotto et 
al., 2016), and a close association between Replication Timing and transcription, with 
regions with high transcriptional activity usually being replicated early in S phase, and 
silenced genes or gene-poor regions in late-S phase (Fraser, 2013; Huvet et al., 2007; 
Rivera-Mulia et al., 2015). 
One of the best studied mechanisms through which PML-RARα exerts its oncogenic 
function is its repressive activity on transcription that is achieved by its direct binding to 
DNA and by the recruitment of chromatin modifiers, such histone deacetylases (HDACs) 
and DNA methyltransferases (DNMTs) to the promoter of its target genes (Grignani et al., 
1998; Croce et al., 2002). 
Since Repli-seq profiles did not show macroscopic differences between the two 
experimental condition, in an attempt to easily highlight reliable differences, we decided to 
focus our attention on changes of Replication Timing occurring within ORI-containing 
Regions (“Valleys”) common to the two experimental conditions. 
By applying the DART pipeline to our Repli-seq datasets, we retrieved 1,717 and 1,707 
Valleys for, respectively, the Zinc-treated and Untreated cells.  
We concentrated our further analyses on 1,379 common Valleys showing an overlap 
higher than 60% of their contigs (Jaccard index ≥0.66), in order to test them for differences 
in distributions of S50 values (i.e. our quantitative measure of the Replication Timing). 
Among the common Valleys, we identified 536 which showed a late-to-early (LtoE-shifted 
Valleys) shift of Replication Timing, 414 showing an early-to-late shift of Replication 
Timing (EtoL-shifted Valleys) and 429 without differences in Replication timing when 
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comparing cells expressing PML-RARα and Untreated cells (Stable Valleys).  
After a further step of filtering, based on thresholds defined with a ROC curve analysis, we 
finally came out with our final set of differently replicated regions: 440 LtoE-, 183 EtoL-
shifted (that altogether covered about 5.5% of the genome) and 451 Stable Valleys, for a 
total of 1,074 regions. 
Following PML-RARα expression, we therefore observed measurable changes of 
Replication Timing giving rise to both late-to-early and early-to-late shifts. 
These results are in line with the ones obtained by an earlier study conducted by Ryba and 
colleagues on several leukemic paediatric patients (Ryba et al., 2012), where the authors 
showed that almost all patients showed deregulation of Replication Timing, with ~8% and 
~5% of the genome showing late-to-early and early-to-late shifts in Replication Timing.  
 
The novelty of our results - besides enhancing the resolution of the Replication Timing of 
several layers (from two to six different S-sub-phases) - is the possibility to investigate at 
the molecular level one of the mechanisms underlying the observed changes following 
oncogene expression.  
 
Interestingly, characterization of Differently Replicated regions revealed that LtoE- and 
EtoL-shifted Valleys showed peculiar traits. 
 
 
 
 
EtoL shift amplitudes in Replication Timing are smaller 
than LtoE ones 
 
 108 
 
The extent of the timing variation (Diff_S50) was wider in the LtoE-shifted Valleys than in 
the EtoL-shifted ones. Probably for that reason, the last stringent filtering step we applied 
drops the number of originally identified EtoL-shifted Valleys of more than 50%.  
Additional replicates may improve sensitivity for the identification of this specific class of 
regions, telling us if they exist or were just a peculiar feature of the samples taken in study.   
 
Changes in Replication Timing induced by the PML-
RAR expression involve regions normally replicated in 
different moments of the S phase 
 
We also observed that LtoE and EtoL shifts of the Replication Timing took place in 
different time windows of the S-phase and, notably, both are not evenly spread. Indeed, 
LtoE shifts mainly involved Valleys replicating in Middle-S phase (S3-S4 S-phase 
fractions). On the other hand, early-to-late shifts were mainly observed in regions 
replicating during Early-S phase. Due to fractionation of S-phase in 6 temporal windows 
(based on the ranges of the sorting gates), we observed a comparable number of shifts in 
Replication Timing within the same S-phase fraction, or from one S-phase fraction to 
closest (towards either earlier- or later-S).  
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EtoL-shifted Valleys are more enriched for PML-RARα 
binding sites than LtoE-shifted ones. 
 
A very interesting feature of LtoE- and EtoL-shifted Valleys was their different content in 
PML-RARα peaks. 
We found that, when compared to Stable and LtoE-shifted Valleys, EtoL-shifted ones were 
significantly enriched for PML-RARα binding sites, with 1,654 peaks in 183 Valleys, with 
an average of 9 peaks per Valleys.  
LtoE-shifted Valleys, on the other hand, were significantly depleted for PML-RARα peak, 
showing 1,091 binding sites in 440 Valleys, with an average of 2 peaks per Valley.  
 
Transcription of genes lying in Differently Replicating 
regions reflects their Replication timing and changes  
 
This observation allowed the study of a possible direct involvement of PML-RARα in the 
deregulation of Replication Timing, by integration of Repli-seq and ChIP-seq data. 
Consistent with previous observations, and with several studies that already demonstrated a 
strict mechanistically connection between replication and transcription ((Dellino et al., 
2013b, 2013b; Fraser, 2013; Huvet et al., 2007; Miotto et al., 2016; Rivera-Mulia et al., 
2015), we found that mean expression levels of genes located in the three classes of 
Valleys reflected their distribution along the S phase, with early-replicating regions 
containing high level of transcription.  
More interestingly, variations in Replication Timing in Valleys replicating during a certain 
time window of the S phase, associated to specific changes in expression levels of the 
genes mapping within the same Valleys following PML-RAR induction.  
Indeed, genes within LtoE-shifted Valleys, mainly in S3 were up-regulated, whereas genes 
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within EtoL-shifted Valleys were Down-regulated at very early S sub-phases. 
 Overall, these data show that EtoL-shifted Valleys (at t=24 hours) are associated with 
PML-RARα - mediated transcription repression which takes place 16 hours earlier (at t=8 
hours) in normally early-replicating regions, while in LtoE-shifted Valleys (at t=24 hours) 
PML-RAR causes transcription induction (at t=8 hours) in regions normally replicating 
later in Middle-S phase. 
 
 
 
EtoL-Shifted Valleys are enriched for direct, promoter-
bound, Down-regulated PML-RARα targets; LtoE-
Shifted Valleys contain both up- and down-regulated 
direct PML-RARα targets 
 
When we determined if the transcriptionally deregulated genes present in Differently 
Replicated Valleys were also directly bound by PML-RARα, we observed a striking 
segregation of states. 
Indeed, in regions showing a EtoL-shifted Replication timing about, ~74% (176/237) of 
Down-regulated genes (which account for 91% of total deregulated genes in these regions 
– 237/260) were also bound by PML-RAR on their promoter, against only a ~ 22% 
(n=5/23) of up-regulated genes. 
Conversely, in LtoE-shifted Valleys, where up-regulated genes account for ~77% 
(169/219) of total deregulated genes, there was not a clear difference in PML-RARα 
binding for up-regulated (~60% - 102/169) or down-regulated (~72% - 36/50) genes.  
Interestingly though, also for this class of Valleys, down-regulated genes seemed to have 
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an higher affinity for PML-RARα binding onto their promoters (~66% - 33/50) than up-
regulated genes (~37%, 63/169). 
Thus, simplifying, we could state that relationship between Replication Timing changes 
and transcriptional deregulation fostered by the oncogene could be differently enacted for 
EtoL- and LtoE-shifted Valleys.  
In EtoL-shifted Valleys, PML-RARmight elicit its oncogenic role by directly binding 
onto the promoters its target genes, inducing a transcriptionally repressed state, rather the 
inducing an increased expression. Indeed, since up-regulated genes in EtoL-shifted Valleys 
are present in such a small number, their contribution to deregulation of Replication 
Timing might be negligible when compared to the one given by down-regulated genes.  
In LtoE-shifted Valleys, instead, oncogenic activity of PML-RARexerted in a dual 
manner, with i) PML-RARbinding directly to the promoters of its down-regulated targets 
and ii) with a direct binding of the oncogene upon the regions located within gene-bodies 
of up-regulated genes, thus possibly involving binding to enhancers and/or both mapped 
and unmapped alternative TSSs. 
 
 
LtoE and EtoL shifts in Replication timing associate with 
PML-RARα-mediated enhancement and suppression of 
biological processes known to be associated with 
tumorigenic transformation. 
 
To gain the status of cancer cell, normal cells need to undergo a series of aberrant events 
which will confer them “hallmark” tumorigenic traits, such as immortalization, increased 
proliferation and invasiveness.  (Hanahan and Weinberg, 2011).  
Such events can be interpreted as modifications in the balance between gene networks or 
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alteration of whole biological pathways. 
In accordance with this, when performing the GO Analysis on our samples, we found that 
several key biological processes were altered after the expression of PML-RARα.  
In addition, we found that deregulated biological processes involved direct PML-RARα 
targets, thus suggesting both a direct and indirect role of the oncogene in the deregulation 
of such processes. 
 
Among the altered biological processes, we could observe an induction of those conferring 
survival advantages in LtoE-shifted Valleys, such as autophagy, glucose metabolism and 
negative regulation of cell ageing.  
Indeed, in literature, there are several evidences showing how aberrancy in such processes 
might confer an advantage in cancer cells.  
Due to its cytoprotective role, abnormal autophagy has been shown to play a consistent 
role in cancer and oncogenic transformation by protecting the cell from apoptotic signals 
and preventing cell death due to low nutrients, metabolic stress and deprivation of growth 
factors (Boya et al., 2005; Jin and White, 2007; Lum et al., 2005). Particularly, Huang and 
colleagues (Huang et al., 2011), showed that PML-RARα expression results in a 
constitutive activation of autophagy, given as an increased formation of autophagosomes. 
On the other hand, different studies have shown that cancer cells have an enhanced glucose 
metabolism (Kroemer and Pouyssegur, 2008), and in a recent investigation (Chen et al., 
2014) it was shown that patients affected by Acute Myeloid Leukemia presented an altered 
glucose metabolism signature. 
Finally, regarding the negative regulation of cell ageing, it is known that a necessary 
condition toward oncogenic transformation is the acquisition by the cell of the ability to 
escape senescence (Hanahan and Weinberg, 2011). 
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When performing the GO Analysis in EtoL-shifted Valleys, we found a negative regulation 
of leukaemia key processes, such as myeloid differentiation process and regulation of 
chromosome organization (being Acute Promyelocytic Leukemia characterized by a block 
of myeloid cells in the promyelocytic state and a reciprocal translocation between 
chromosomes 15 and 17). 
Other important processes being inhibited were the negative regulation of telomere 
maintenance and NIK/NF-kappaB signalling, both being pervasively described in literature 
as key processes for oncogenic transformation (Cong et al., 2002; Hoesel and Schmid, 
2013; Lopez-Guerra and Colomer, 2010; Luo et al., 2005; Reddel, 2014; Samassekou et 
al., 2009). 
Taken together, these results possibly confirm the trend observed for deregulated genes in 
LtoE- and EtoL-shifted Valleys, resulting in PML-RARα acting by both direct and indirect 
mechanisms, with the abnormal activation in LtoE-shifted Valleys, or inhibition in EtoL-
shifted Valleys, of biological processes which have been described as fundamental to 
achieve an oncogenic transformation.  
 
 
 
 
 
 
 114 
 
LtoE-, EtoL-shifted and Stable Valleys are characterized 
by pre-existing different assets of epigenetic 
modifications, which coherently change after the 
expression of the PML-RARα oncogene 
 
Several authors have shown that PML-RARα exerts part of its oncogenic function by 
modifying epigenetic markers (Croce et al., 2002; Grignani et al., 1998; Hoemme et al., 
2008; Saeed et al., 2011; Villa et al., 2007), while others have shown an association 
between chromatin structure and Replication Timing (Aparicio et al., 2004; Bell et al., 
2010; Gilbert et al., 2004; Goren et al., 2008; Hiratani and Gilbert, 2010; Ryba et al., 2010; 
Vogelauer et al., 2002a; Zappulla et al., 2002). Therefore, it is not surprising that within 
LtoE- and EtoL-shifted Valleys, ChIP-sequencing signals of three histone marks 
classically linked to an “active state” of the chromatin (H3K4me3, H3K4me1 and 
H3K27Ac), were truly different: for all the three markers, compared to the Stable Valleys, 
the LtoE- and EtoL-shifted Valleys showed significantly lower and significantly higher 
levels, respectively.  
Moreover, consistent with the observed changes in transcription (at t=8 hours) and 
replication timing (at t=24 hours), following PML-RARα induction, we observed a 
significant increase, and a parallel significant decrease, for both H3K4me3 and H3K27Ac 
markers in LtoE- and EtoL-shifted Valleys. 
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Our proposed model 
Altogether, the evidences collected in this study, although preliminary, prompt us to 
propose a possible model by which PML-RARα might impact on DNA Replication, 
eliciting both late-to-early, in greater extent, and early-to-late shifts of the Replication 
Timing.  
Our hypothesis is that PML-RARα expression, by changing gene transcription and 
chromatin organization, alters normal DNA Replication Timing mainly in a direct manner, 
through its binding to open chromatin regions marked by histone modifications such as 
H3K4me3, H3K4me1 and H3K27ac. 
It is difficult, at this stage, to conclude that a clear epistatic relationship exists between 
changes of transcription/chromatin organization induced by the oncogene and shifts of 
replication timing measured in our experimental model; however, alterations of 
transcription and chromatin structure following PML-RAR expression at early time 
points, observed at the same Valleys (i.e., DNA replication origin-containing regions) 
that, later on, show significant changes of Replication Timing, deserve further 
investigations.  
Furthermore, identification of genomic regions showing changes of replication timing, 
now possible thanks to DART analysis, is instrumental for the identification, in space 
and time, at the genome scale, of potential sites of genomic instability deriving from 
unscheduled collisions between transcription and replication machineries.  
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